[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 97 of about 97
1. Choi GS, Park IJ, Kang BM, Lim KH, Jun SH: A novel approach of robotic-assisted anterior resection with transanal or transvaginal retrieval of the specimen for colorectal cancer. Surg Endosc; 2009 Dec;23(12):2831-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel approach of robotic-assisted anterior resection with transanal or transvaginal retrieval of the specimen for colorectal cancer.
  • The tumor stage was I in four, II in two, and III in seven patients.
  • CONCLUSION: Robotic-assisted laparoscopic methods were safe for AR in patients with colorectal cancer.
  • [MeSH-minor] Adult. Aged. Anal Canal. Female. Humans. Length of Stay. Male. Middle Aged. Vagina

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2001 Nov;25(11):1408-11 [11760744.001]
  • [Cites] Surg Endosc. 2002 Sep;16(9):1267-70 [12235507.001]
  • [Cites] Int J Gynaecol Obstet. 2005 Oct;91(1):27-31 [16051243.001]
  • [Cites] Fertil Steril. 2000 May;73(5):1040-2 [10785235.001]
  • [Cites] J Am Assoc Gynecol Laparosc. 2004 Feb;11(1):42-6 [15104829.001]
  • [Cites] Arch Surg. 2003 Jul;138(7):777-84 [12860761.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3168-73 [17763911.001]
  • [Cites] Dis Colon Rectum. 2002 Dec;45(12):1689-94; discussion 1695-6 [12473897.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2002 Feb;12(1):1-5 [12008756.001]
  • [Cites] Surg Endosc. 2003 Oct;17(10):1521-4 [12915974.001]
  • [Cites] Int J Colorectal Dis. 2008 Jul;23(7):703-7 [18379795.001]
  • [Cites] Surg Endosc. 2001 Sep;15(9):918-23 [11605106.001]
  • [Cites] Surg Endosc. 2006 Nov;20(11):1713-8 [17008953.001]
  • [Cites] Fertil Steril. 1996 Jan;65(1):193-7 [8557141.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2162-8 [15657669.001]
  • [Cites] J Urol. 2001 Jun;165(6 Pt 1):1964-6 [11371890.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2002 Feb;12(1):41-5 [12008761.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S330-3 [11821833.001]
  • [Cites] Surg Endosc. 2002 Oct;16(10):1389-402 [12140630.001]
  • [Cites] Surg Endosc. 2008 Mar;22(3):792-7 [18027033.001]
  • [Cites] Surg Endosc. 2006 Oct;20(10):1521-5 [16897284.001]
  • [Cites] Surg Endosc. 2002 Dec;16(12):1691-6 [12140631.001]
  • [Cites] Heart Surg Forum. 2001;4(4):307-10 [11827857.001]
  • (PMID = 19440794.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Video-Audio Media
  • [Publication-country] Germany
  •  go-up   go-down


2. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Gray R: Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res; 2009 Dec 15;15(24):7693-7700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer.
  • PURPOSE: To perform an exploratory analysis of the relationship between gene expression and recurrence in operable hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-normal breast cancer patients treated with adjuvant doxorubicin-containing chemotherapy.
  • EXPERIMENTAL DESIGN: RNA was extracted from archived tumor samples derived from 378 patients with stage I to III HR-positive, HER2-normal breast cancer and analyzed by reverse transcription-PCR for a panel of 374 genes, including the 21-gene recurrence score (RS).
  • CONCLUSIONS: In patients with HR-positive, HER2-normal breast cancer, a population known to have a low incidence of TOP2A gene alterations thought to be predictive of anthracycline benefit, there is a range of TOP2A RNA expression that is strongly associated with recurrence after adjuvant anthracyclines, which provides information complementary to RS, indicating that it merits further evaluation as a prognostic and predictive marker. (Clin Cancer Res 2009;15(24):7693-700).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19996222.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / U10 CA014958-28; United States / NCI NIH HHS / CA / U10 CA014958-32; United States / NCI NIH HHS / CA / U10 CA014958-29; United States / NCI NIH HHS / CA / U10 CA014958-31; United States / NCI NIH HHS / CA / U10 CA014958; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA014958-33; United States / NCI NIH HHS / CA / U10 CA014958-30; United States / NCI NIH HHS / CA / U10 CA066636; United States / NCI NIH HHS / CA / U10 CA014958-34; United States / NCI NIH HHS / CA / U10 CA014958-35; United States / NCI NIH HHS / CA / U10 CA023318; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / U24 CA114737
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Schöllnberger H, Stewart RD, Mitchel RE: Low-LET-induced radioprotective mechanisms within a stochastic two-stage cancer model. Dose Response; 2005;3(4):508-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-LET-induced radioprotective mechanisms within a stochastic two-stage cancer model.
  • A stochastic two-stage cancer model with clonal expansion was used to investigate the potential impact on human lung cancer incidence of some aspects of the hormesis mechanisms suggested by Feinendegen (Health Phys.
  • Sensitivity studies were conducted to identify critical model inputs and to help define the changes in cellular defense mechanisms necessary to produce a lifetime probability for lung cancer that deviates from a linear no-threshold (LNT) type of response.
  • Our studies suggest that lung cancer risk predictions may be very sensitive to the induction of DNA damage by endogenous processes.
  • When both repair and scavengers are considered as inducible, radiation must enhance DNA repair and radical scavenging in excess of 30 to 40% of the baseline values to produce lifetime probabilities for lung cancer outside the range expected for endogenous processes and background radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):674-9 [11237389.001]
  • [Cites] Radiat Res. 2002 Aug;158(2):181-6 [12105988.001]
  • [Cites] Int J Radiat Biol. 2000 Oct;76(10):1365-75 [11057745.001]
  • [Cites] Radiat Res. 2000 Aug;154(2):178-86 [10931690.001]
  • [Cites] Mutat Res. 2000 Jan 17;447(1):73-116 [10686307.001]
  • [Cites] Mutat Res. 1999 Sep 13;435(1):43-61 [10526216.001]
  • [Cites] Int J Radiat Biol. 1999 Sep;75(9):1189-99 [10528927.001]
  • [Cites] Radiat Res. 1999 Sep;152(3):273-9 [10453088.001]
  • [Cites] Radiat Environ Biophys. 1999 May;38(1):57-71 [10384956.001]
  • [Cites] Science. 1998 May 15;280(5366):1066-9 [9582118.001]
  • [Cites] Radiat Res. 1998 May;149(5):517-20 [9588363.001]
  • [Cites] Radiat Environ Biophys. 1997 Jun;36(2):85-8 [9271795.001]
  • [Cites] Risk Anal. 1997 Jun;17(3):391-9 [9232020.001]
  • [Cites] Radiat Environ Biophys. 1997 Feb;36(1):45-58 [9128898.001]
  • [Cites] Radiat Environ Biophys. 1996 May;35(2):127-9 [8792461.001]
  • [Cites] Radiat Res. 1996 Nov;146(5):582-5 [8896586.001]
  • [Cites] Radiat Res. 1996 Oct;146(4):369-73 [8927708.001]
  • [Cites] Mutat Res. 1996 Sep 23;356(2):209-16 [8841487.001]
  • [Cites] Histol Histopathol. 1996 Jan;11(1):237-55 [8720467.001]
  • [Cites] Biometrics. 1995 Dec;51(4):1278-91 [8589222.001]
  • [Cites] Risk Anal. 1994 Dec;14(6):1079-80 [7846315.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S68-97 [8127953.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S17-67 [8127952.001]
  • [Cites] Risk Anal. 1993 Jun;13(3):273-9 [8341806.001]
  • [Cites] Free Radic Biol Med. 1991;11(3):299-306 [1937147.001]
  • [Cites] N Engl J Med. 1989 Nov 9;321(19):1285-9 [2797101.001]
  • [Cites] Risk Anal. 1990 Jun;10(2):323-41 [2195604.001]
  • [Cites] J Natl Cancer Inst. 1981 Jun;66(6):1037-52 [6941039.001]
  • [Cites] J Natl Cancer Inst. 1978 Jul;61(1):49-52 [276637.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13761-6 [14610281.001]
  • [Cites] Int J Radiat Biol. 2003 Apr;79(4):235-40 [12775447.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62 [12679524.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):767-74 [12618888.001]
  • [Cites] Nature. 2003 Feb 13;421(6924):691-2 [12610596.001]
  • [Cites] Radiat Res. 2003 Mar;159(3):433-6 [12600247.001]
  • [Cites] Ann ICRP. 2006;36(1-2):25-327, iii [17188183.001]
  • [Cites] Risk Anal. 2001 Feb;21(1):103-5 [11332539.001]
  • [Cites] Radiat Res. 2001 Dec;156(6):700-7 [11741493.001]
  • [Cites] Radiat Res. 2003 Mar;159(3):320-7 [12600234.001]
  • [Cites] Int J Radiat Biol. 2002 Dec;78(12):1139-47 [12556341.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6B):4115-39 [11205238.001]
  • (PMID = 18648628.001).
  • [ISSN] 1559-3258
  • [Journal-full-title] Dose-response : a publication of International Hormesis Society
  • [ISO-abbreviation] Dose Response
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2477198
  • [Keywords] NOTNLM ; LNT / endogenous damage / hormesis / low-LET / lung cancer / radioprotective mechanisms / threshold
  •  go-up   go-down


Advertisement
4. Temple LK, Romanus D, Niland J, Veer AT, Weiser MR, Skibber J, Wilson J, Rajput A, Benson A, Wong YN, Schrag D: Factors associated with sphincter-preserving surgery for rectal cancer at national comprehensive cancer network centers. Ann Surg; 2009 Aug;250(2):260-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with sphincter-preserving surgery for rectal cancer at national comprehensive cancer network centers.
  • OBJECTIVE: To determine rate and predictors of sphincter-preserving surgery (SPS) for rectal cancer patients treated at specialty institutions.
  • Evidence of association between case volume and SPS rate has prompted recommendations that all rectal cancer patients undergo surgery at specialty institutions.
  • METHODS: A prospective registry of all colorectal cancer patients treated at 7 National Comprehensive Cancer Network institutions was used to identify patients with clinical stage I-III rectal cancer undergoing surgery (n = 674) between September 2005 and October 2007.
  • CONCLUSIONS: SPS rates at National Comprehensive Cancer Network institutions exceed those seen in population-based samples and clinical trials.
  • [MeSH-major] Anal Canal. Rectal Neoplasms / surgery


5. Retèl VP, Hummel MJ, van Harten WH: Review on early technology assessments of nanotechnologies in oncology. Mol Oncol; 2009 Dec;3(5-6):394-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nanotechnology is expected to play an increasingly important role in the diagnostics, prognostics, and management of targeted cancer treatments.
  • Here we present an overview of the literature on the technology assessments that have already been undertaken on early stage nanotechnology in cancer care, with particular emphasis placed on clinical efficacy, efficiency, logistics, patient-related features and technology dynamics.
  • Owing to the current stage of development of most nanotechnologies, we found only a limited number of publications describing the application of either Health Technology Assessment (HTA) or Constructive Technology Assessment (CTA).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2007 Nov;53(11):2002-9 [17890442.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):97-110 [18227410.001]
  • [Cites] Int J Technol Assess Health Care. 2009 Jan;25(1):73-83 [19126254.001]
  • [Cites] Tumori. 2008 Mar-Apr;94(2):284-90 [18564618.001]
  • [Cites] J Cancer Res Ther. 2006 Oct-Dec;2(4):186-95 [17998702.001]
  • [Cites] Genet Med. 2005 Jul-Aug;7(6):380-9 [16024969.001]
  • [Cites] Environ Health Perspect. 2006 Feb;114(2):165-72 [16451849.001]
  • [Cites] Int J Technol Assess Health Care. 2007 Fall;23 (4):425-32 [17937829.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1087-93 [17529967.001]
  • [Cites] Nat Biotechnol. 2004 Jan;22(1):93-7 [14661026.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2160-8 [12412170.001]
  • [Cites] Ann Oncol. 2002 Oct;13(10 ):1590-7 [12377647.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1002-7 [12966416.001]
  • [Cites] Mol Oncol. 2009 Dec;3(5-6):394-401 [19540817.001]
  • [Cites] Int J Technol Assess Health Care. 2008 Winter;24(1):36-44 [18218167.001]
  • [Cites] HIV Clin Trials. 2006 Jul-Aug;7(4):194-202 [17065031.001]
  • [Cites] Clin Ther. 2003 Jun;25(6):1826-45 [12860501.001]
  • [Cites] Ann Oncol. 2006 Oct;17(10):1560-7 [16790517.001]
  • [Cites] J Nanosci Nanotechnol. 2007 Sep;7(9):3048-70 [18019130.001]
  • [Cites] J Law Med Ethics. 2006 Winter;34(4):704-13 [17199812.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1263-8 [16740598.001]
  • [Cites] Acta Oncol. 1999;38(8):1063-7 [10665764.001]
  • [Cites] Int J Technol Assess Health Care. 2007 Spring;23(2):162-8 [17493301.001]
  • [Cites] Oncologist. 2007 Mar;12(3):301-11 [17405894.001]
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):41-6 [12459735.001]
  • [Cites] Health Technol Assess. 1997;1(14 ):i-vi, 1-149 [9483162.001]
  • [Cites] Med Princ Pract. 2008;17(2):89-101 [18287791.001]
  • [Cites] Genome Res. 2007 Feb;17(2):240-8 [17189378.001]
  • [Cites] J Oncol Pharm Pract. 2009 Jun;15(2):67-78 [19036903.001]
  • [Cites] J Law Med. 2007 Aug;15(1):128-35 [17902495.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):786-92 [17141975.001]
  • [Cites] Anal Bioanal Chem. 2006 Feb;384(3):620-30 [16440195.001]
  • [Cites] Health Technol Assess. 2002;6(23 ):1-119 [12433314.001]
  • [Cites] Technol Cancer Res Treat. 2005 Dec;4(6):645-50 [16292884.001]
  • [Cites] Expert Rev Mol Diagn. 2003 Mar;3(2):153-61 [12647993.001]
  • [Cites] Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv [16545208.001]
  • [Cites] Oral Oncol. 2004 Apr;40(4):372-82 [14969816.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Apr;7 Suppl 4:S150-5 [17562253.001]
  • [Cites] Technol Cancer Res Treat. 2008 Feb;7(1):1-13 [18198919.001]
  • [Cites] Nat Genet. 2007 Mar;39(3):352-8 [17293864.001]
  • [Cites] Mol Oncol. 2008 Aug;2(2):153-60 [19383334.001]
  • [Cites] Oral Oncol. 2007 Apr;43(4):358-65 [16920382.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):267-9 [17108940.001]
  • [Cites] Med J Aust. 2007 Feb 19;186(4):189-91 [17309421.001]
  • (PMID = 19540817.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 54
  •  go-up   go-down


6. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • Ten patients (18 percent) had an American Society of Anesthesiologists' classification of III.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • Of those who underwent curative resection (Stages I-III), the distal resection margin was 2.9 +/- 0.7 cm (mean +/- standard error) and the radial resection margins were at least 2 mm in all patients.
  • The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the anal verge; a coloanal pull-through anastomosis was required in one patient who had a distal cancer.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • This brought the rectum proximally and anteriorly, aiding with the laparoscopic stapler transection of the distal rectum, especially if the cancer was distal, the patient was obese, and the pelvis was narrow.
  • Further randomized, controlled studies that include assessing five-year cancer survival/recurrence, pelvic nerve dysfunction, and bowel function are needed before laparoscopic ultralow anterior resection becomes widely accepted.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


7. Sinha S, Sinha N, Bandyopadhyay R, Mondal SK: Robinson's cytological grading on aspirates of breast carcinoma: Correlation with Bloom Richardson's histological grading. J Cytol; 2009 Oct;26(4):140-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robinson's cytological grading on aspirates of breast carcinoma: Correlation with Bloom Richardson's histological grading.
  • BACKGROUND: Cytological grading (CG) on aspirates of breast carcinoma is a useful tool for surgical maneuver and prognosis.
  • AIMS: An endeavor was made to use CG on aspirates of breast carcinoma using Robinson's grade and to correlate it with Bloom Richardsons' histopathological grading.
  • MATERIALS AND METHODS: A total of 59 patients of breast carcinoma, aged 28-57 years, were aspirated and the smears were graded using Robinson's criteria.
  • For grade I and II tumors, there was substantial strength of agreement between cytology and histopathology, while in grade III, the concordance was nearly perfect.
  • Lymph node metastasis was observed in three with cytological grade II, 28 of grade III and none of grade I.
  • All grade I had stage A, two of grade II had stage B, while all grade III had either stage B or stage C disease.
  • CONCLUSIONS: Thus, CG of breast carcinoma correlates well with histopathological grading and may well be useful as a prognostic marker.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Anal Quant Cytol Histol. 1987 Dec;9(6):480-4 [2829937.001]
  • [Cites] Lancet. 1994 Apr 16;343(8903):947-9 [7909010.001]
  • [Cites] Diagn Cytopathol. 1997 Apr;16(4):295-311 [9143822.001]
  • [Cites] Cancer. 1997 Feb 25;81(1):16-21 [9100536.001]
  • [Cites] Diagn Cytopathol. 1995 Oct;13(3):260-5 [8575287.001]
  • [Cites] Diagn Cytopathol. 1995 Dec;13(5):388-95 [8834313.001]
  • [Cites] Diagn Cytopathol. 1996 Aug;15(2):116-20 [8872432.001]
  • [Cites] Diagn Cytopathol. 1994;10(3):203-8 [8050325.001]
  • (PMID = 21938177.001).
  • [ISSN] 0974-5165
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3167998
  • [Keywords] NOTNLM ; Bloom Richardson's grading / Breast carcinoma / Robinson's grading / fine needle aspiration cytology
  •  go-up   go-down


8. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A: Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum; 2009 Apr;52(4):624-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.
  • PURPOSE: The objective of this study was to assess survival and prognostic factors for anal carcinoma in the population.
  • METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000).
  • Concordance was calculated to assess agreement between American Joint Committee on Cancer stage and actual outcome.
  • RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent).
  • The American Joint Committee on Cancer (6th edition) staging system provided good survival discrimination by stage: I, 69.5 percent; II, 59.0 percent; III, 40.6 percent; and IV, 18.7 percent (concordance index, 0.663).
  • On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, >or=65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001).
  • CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality


9. Ballonoff A, Kavanagh B, McCarter M, Kane M, Pearlman N, Nash R, Shah RJ, Raben D, Schefter TE: Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol; 2008 Jun;31(3):264-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial.
  • OBJECTIVES: A prospective phase II trial was conducted to evaluate the feasibility, safety, and pathologic response rate of preoperative capecitabine and accelerated synchronous integrated boost (SIB) intensity-modulated radiotherapy (IMRT) in patients with locally advanced rectal cancer.
  • METHODS: Consenting operable patients with stage II or III adenocarcinoma of the rectum received capecitabine (825 mg/m2 PO BID, 5 days/wk x 5 weeks) and SIB-IMRT delivering 55 Gy (2.2 Gy/fraction) to the gross tumor while simultaneously delivering 45 Gy (1.8 Gy/fraction) to the regional lymph nodes and areas at risk for harboring microscopic disease.
  • A single pathologist analyzed the resected tumor's TNM stage and Mandard regression/response scores.
  • Of 3 patients who had tumors within 5 cm of the anal verge, 2 underwent sphincter-sparing procedures.
  • CONCLUSIONS: Preoperative chemoradiation with capecitabine and SIB-IMRT is well tolerated and results in an encouraging pCR rate for patients with locally advanced rectal cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525306.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Meyer-Siegler KL, Cox J, Leng L, Bucala R, Vera PL: Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation. Cancer Lett; 2010 Apr 1;290(1):49-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation.
  • The present study identifies anti-thrombin III (ATIII) as an endogenous MIF binding protein, which reduces MIF biological activity.
  • Serum MIF in bladder cancer patients (TCC stage II, n=50) was increased when compared to normal patients (n=50), while ATIII-MIF complexes were decreased in bladder cancer patient serum.
  • These data suggest that increased circulating levels of bioactive MIF are present in bladder cancer patient serum.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ireland Ltd.
  • [Cites] Nat Med. 2000 Feb;6(2):164-70 [10655104.001]
  • [Cites] Mediators Inflamm. 2009;2009:535348 [19325914.001]
  • [Cites] Transplantation. 2001 Jun 27;71(12):1777-83 [11455258.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1449-56 [11920501.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4015-20 [12010802.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2053-63 [12466122.001]
  • [Cites] Trends Cardiovasc Med. 2002 Nov;12(8):331-8 [12536119.001]
  • [Cites] Immunol Cell Biol. 2003 Apr;81(2):137-43 [12631237.001]
  • [Cites] Expert Opin Ther Targets. 2003 Apr;7(2):153-64 [12667094.001]
  • [Cites] J Endotoxin Res. 2003;9(2):119-23 [12803886.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13729-37 [14736878.001]
  • [Cites] BMC Cancer. 2004 Jul 12;4:34 [15248897.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1504-9 [15371880.001]
  • [Cites] Am J Clin Pathol. 1978 Feb;69(2):194-5 [629228.001]
  • [Cites] J Clin Pathol. 1979 Jan;32(1):21-5 [429575.001]
  • [Cites] Thromb Haemost. 1981 Aug 28;46(2):500-3 [7302888.001]
  • [Cites] J Urol. 1982 Jul;128(1):72-4 [7109075.001]
  • [Cites] Am J Med. 1989 Sep 11;87(3B):10S-14S [2552799.001]
  • [Cites] Thromb Haemost. 1996 Dec;76(6):897-901 [8972008.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19393-400 [9235938.001]
  • [Cites] Int J Hematol. 1998 Jul;68(1):67-78 [9713170.001]
  • [Cites] BMC Cancer. 2005;5:73 [16000172.001]
  • [Cites] J Biol Chem. 2005 Nov 4;280(44):36541-4 [16115897.001]
  • [Cites] Eur J Immunol. 2005 Dec;35(12):3405-13 [16224818.001]
  • [Cites] World J Gastroenterol. 2006 Jan 7;12(1):60-5 [16440418.001]
  • [Cites] J Urol. 2006 Apr;175(4):1523-8 [16516040.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8730-9 [17142775.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3100-12 [17496909.001]
  • [Cites] Mol Endocrinol. 2007 Jun;21(6):1267-80 [17389748.001]
  • [Cites] Autoimmun Rev. 2007 Nov;7(1):8-11 [17967718.001]
  • [Cites] Electrophoresis. 2007 Dec;28(23):4302-10 [18041032.001]
  • [Cites] Intensive Care Med. 2008 Feb;34(2):361-7 [17940748.001]
  • [Cites] Inflamm Res. 2008 Feb;57(2):45-50 [18288453.001]
  • [Cites] J Cell Physiol. 2008 Jun;215(3):665-75 [18064633.001]
  • [Cites] Oncology. 2008;75(3-4):127-33 [18791328.001]
  • [Cites] J Clin Invest. 2008 Nov;118(11):3533-6 [18982159.001]
  • [Cites] J Cell Biochem. 2008 Dec 1;105(5):1279-88 [18821572.001]
  • [Cites] Mol Cell Biol. 2009 Apr;29(7):1922-32 [19188446.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1117-23 [10666179.001]
  • (PMID = 19762145.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK075059; United States / NIAID NIH HHS / AI / R01 AI042310-06; United States / NIDDK NIH HHS / DK / DK075059; United States / NIAID NIH HHS / AI / R01 AI042310; United States / NIDDK NIH HHS / DK / DK075059-02; United States / NIDDK NIH HHS / DK / R21 DK075059-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Macrophage Migration-Inhibitory Factors; 0 / Multiprotein Complexes; 9000-94-6 / Antithrombin III
  • [Other-IDs] NLM/ NIHMS146096; NLM/ PMC2832085
  •  go-up   go-down


11. Dai Y, Jiang JB, Bi DS, Jin ZT, Sun JZ, Hu SY: Preservation of the continence function after intersphincteric resection using a prolapsing technique in the patients with low rectal cancer and its clinical prognosis. Chin Med J (Engl); 2008 Oct 20;121(20):2016-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preservation of the continence function after intersphincteric resection using a prolapsing technique in the patients with low rectal cancer and its clinical prognosis.
  • BACKGROUND: The technique of intersphincteric resection of tumors combined with coloanal anastomosis has been used to avoid permanent colostomy for patients with a rectal cancer located < 5 cm from the anal verge.
  • This study aimed at assessing the preservation of continence function of the residual rectum and the clinical prognosis of patients with lower rectal cancer after intersphincteric resection using a prolapsing technique.
  • (1) pathological evidence of rectal cancer and the tumors within distal margins located 5 cm or less from the anus by preoperative endoscopic examination;.
  • From January 2000 to June 2004, 23 patients with low rectal cancer were included in this study.
  • The patients were followed for assessment of the function of the residual rectum and of cancer recurrence after the operations.
  • RESULTS: The median tumor distance from the anal margin was 4.5 (range 3.5 - 5.0) cm and the mean distal surgical margin 1.6 (range 1.0 - 2.0) cm.
  • Cancer was classified into Stage I (30.4%), Stage II (47.8%), and Stage III (21.7%) according to the TNM classification.
  • Average times of defecation per day of 3, 6, 12, 24 and 36 months after the surgery were 13.1, 4.7, 3.1, 2.9, and 3.2 times/day.
  • Anal manometer measurements showed a decrease of pressure during the resting time after intersphincteric resection and this change remained during the period of follow-up.
  • CONCLUSIONS: More residual rectum function after the surgery may be preserved by intersphincteric resection of low rectum cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080267.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


12. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH: Different patterns of lymphatic spread of sigmoid, rectosigmoid, and rectal cancers. Ann Surg Oncol; 2008 Dec;15(12):3478-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We tried to evaluate the clinicopathological characteristics of rectosigmoid cancer compared with those of sigmoid and rectal cancer.
  • METHODS: We collected data on patients who underwent curative resections for sigmoid (399; SC group), rectosigmoid (175; RS group), and upper rectal cancer (453; RA group) between June 1996 and December 2007.
  • RESULTS: The mean distance from the anal verge was 12.5 cm for rectosigmoid cancer, 13 cm for sigmoid cancer, and 9.8 cm for rectal cancer.
  • For stage III disease, the local recurrence rate was significantly higher in the RA group; the disease-free survival rate was higher in the SC group, and the RS group showed results similar to those of the RA group.
  • CONCLUSION: Clinicopathological characteristics of rectosigmoid cancer were similar to those of sigmoid or rectal cancer.
  • For lymphatic spreads, it was different from sigmoid or rectal cancer and more frequently metastasized to pararectal nodes.
  • Oncologic results were slightly unfavorable to sigmoid colon, and showed data similar to those of rectal cancer.
  • Therefore, rectosigmoid cancer was a "real" classification of colorectal cancer with unique lymphatic spread.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma, Mucinous / secondary. Carcinoma, Signet Ring Cell / secondary. Lymph Nodes / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2010 Jan;17(1):346-7 [19841983.001]
  • (PMID = 18830668.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Yoo JH, Hasegawa H, Ishii Y, Nishibori H, Watanabe M, Kitajima M: Long-term outcome of per anum intersphincteric rectal dissection with direct coloanal anastomosis for lower rectal cancer. Colorectal Dis; 2005 Sep;7(5):434-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of per anum intersphincteric rectal dissection with direct coloanal anastomosis for lower rectal cancer.
  • With direct coloanal anastomosis for cases of lower rectal cancer in which the distal surgical margin is difficult to secure by the double stapling technique.
  • Of these, two patients (one stage 0 and one stage IV) were excluded from the analysis of oncological outcome.
  • There was an association between distant metastasis and TNM or pT stage.
  • The overall survival rates for stage I, II and III were 85%, 80% and 89%, respectively.
  • CONCLUSION: The surgical indications of this operation should be limited to patients with T1 rectal cancer or tumours less than 3 cm.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Fecal Incontinence / epidemiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Proctocolectomy, Restorative. Rectum / surgery. Surveys and Questionnaires. Survival Rate

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16108877.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Park EM, Ramnath N, Yang GY, Ahn JY, Park Y, Lee TY, Shin HS, Yu J, Ip C, Park YM: High superoxide dismutase and low glutathione peroxidase activities in red blood cells predict susceptibility of lung cancer patients to radiation pneumonitis. Free Radic Biol Med; 2007 Jan 15;42(2):280-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High superoxide dismutase and low glutathione peroxidase activities in red blood cells predict susceptibility of lung cancer patients to radiation pneumonitis.
  • Radiation pneumonitis is an unpredictable complication of radiotherapy for lung cancer and a condition which can cause significant morbidity.
  • Superoxide dismutase (SOD), glutathione peroxidase (GPX), and catalase (CAT) activities and glutathione in RBC were measured at baseline and then weekly for 6 weeks of treatment in 15 eligible patients receiving concurrent chemo-radiotherapy for unresectable stage III NSCLC.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Res. 1997 Feb;147(2):245-56 [9008217.001]
  • [Cites] J Natl Cancer Inst. 1996 Sep 4;88(17):1210-5 [8780630.001]
  • [Cites] Exp Lung Res. 1998 May-Jun;24(3):321-37 [9635254.001]
  • [Cites] Free Radic Biol Med. 1998 Jul 1;25(1):79-86 [9655525.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2692-9 [10561343.001]
  • [Cites] J Cell Physiol. 2000 Apr;183(1):100-7 [10699971.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1029-35 [9719112.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):469-78 [9806503.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):318-28 [15667949.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):862-71 [15936571.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):641-8 [11172944.001]
  • [Cites] Int J Radiat Biol. 2000 Apr;76(4):511-6 [10815631.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):899-908 [11429217.001]
  • [Cites] Radiat Res. 2002 Mar;157(3):256-65 [11839087.001]
  • [Cites] Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):26-33 [11917281.001]
  • [Cites] J Natl Cancer Inst. 2002 May 15;94(10):733-41 [12011223.001]
  • [Cites] Free Radic Biol Med. 2003 Mar 15;34(6):689-95 [12633746.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):758-67 [14967431.001]
  • [Cites] Radiother Oncol. 2004 May;71(2):183-9 [15110452.001]
  • [Cites] Anal Biochem. 1989 May 15;179(1):8-18 [2547324.001]
  • [Cites] Radiat Res. 1991 Jun;126(3):349-56 [1852022.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):383-6 [8195038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 9):34-7 [7644926.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2606-12 [7595714.001]
  • [Cites] Radiat Res. 1996 Jun;145(6):762-7 [8643837.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1071-6 [8648359.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6432-7 [9177235.001]
  • (PMID = 17189833.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056-30; United States / NCI NIH HHS / CA / CA109480; United States / NCI NIH HHS / CA / R01 CA109480; United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / R01 CA109480-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase
  • [Other-IDs] NLM/ NIHMS16140; NLM/ PMC1892164
  •  go-up   go-down


15. Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ, Fruehauf JP: Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol; 2009 Mar;112(3):583-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.
  • OBJECTIVES: To determine whether markers of tumor angiogenesis were associated with progression-free survival (PFS) and overall survival (OS) in women with high-risk, early-stage cervical cancer treated on a phase III trial.
  • CONCLUSIONS: Tumor angiogenesis measured by CD31 MVD is an independent prognostic factor for both PFS and OS in high-risk, early-stage cervical cancer.

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5C):4375-8 [10650779.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1069-74 [19139430.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1317-22 [10810442.001]
  • [Cites] Obstet Gynecol. 2000 Aug;96(2):224-8 [10908767.001]
  • [Cites] Oncogene. 2000 Sep 21;19(40):4611-20 [11030150.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):81-8 [11205922.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2907-10 [11306466.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2826-31 [11555600.001]
  • [Cites] Lung Cancer. 2002 May;36(2):143-50 [11955648.001]
  • [Cites] Gynecol Oncol. 2002 Jun;85(3):469-75 [12051876.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):768-79 [12377329.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2677-85 [12746487.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):922-8 [12829126.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4145-50 [14519638.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Dec;25(6):303-11 [14714296.001]
  • [Cites] Cancer J. 2004 Jan-Feb;10(1):27-32 [15000492.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):2988-95 [14968115.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):352-7 [2227547.001]
  • [Cites] J Biol Chem. 1992 Sep 25;267(27):19027-30 [1326540.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1582-4 [7521539.001]
  • [Cites] Anticancer Res. 1995 Jul-Aug;15(4):1549-51 [7544572.001]
  • [Cites] Am J Obstet Gynecol. 1996 Jan;174(1 Pt 1):126-31 [8571995.001]
  • [Cites] Int J Gynecol Pathol. 1995 Apr;14(2):114-8 [8601522.001]
  • [Cites] J Natl Cancer Inst. 1996 Oct 2;88(19):1361-8 [8827013.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):27-33 [9345352.001]
  • [Cites] Br J Cancer. 1997;76(11):1410-5 [9400935.001]
  • [Cites] Am J Obstet Gynecol. 1998 Feb;178(2):314-9 [9500492.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2795-800 [9829744.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):485-9 [10448304.001]
  • [Cites] Br J Cancer. 1999 Sep;81(2):354-8 [10496365.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8405-12 [15623619.001]
  • [Cites] Oral Oncol. 2005 Feb;41(2):147-55 [15695116.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):721-8 [15721417.001]
  • [Cites] Int J Clin Oncol. 2005 Feb;10(1):35-9 [15729599.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):80-3 [16009408.001]
  • [Cites] Microvasc Res. 2007 Sep-Nov;74(2-3):72-84 [17560615.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):112-20 [17936343.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1606-13 [10764420.001]
  • (PMID = 19110305.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA087558-06; United States / NCI NIH HHS / CA / CA037517-19; United States / NCI NIH HHS / CA / CA087558-06; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / K23 CA 087558; United States / NCI NIH HHS / CA / CA027469-23; United States / NCI NIH HHS / CA / CA087558-05; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / U10 CA027469-23; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / P30 CA062203; United States / NCI NIH HHS / CA / K23 CA087558; United States / NCI NIH HHS / CA / K23 CA087558-05; United States / NCI NIH HHS / CA / U10 CA037517-19
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / Thrombospondin 1; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ NIHMS192713; NLM/ PMC2858218
  •  go-up   go-down


16. Sill MW, Sampson AR: Drop-the-Losers Design: Binomial Case. Comput Stat Data Anal; 2009 Jan 1;53(3):586-595
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Drop-the-losers designs were introduced for normal distributions as a method of combining phase II and III clinical trials together under a single protocol with the purpose of more rapidly evaluating drugs by eliminating as much as possible the delays that typically occur between the two phases of clinical development.
  • In the design, the sponsor would administer k treatments along with a control in the first stage.
  • During a brief interim period, efficacy data would be used to select the best treatment (with a rule to deal with ties) for further evaluation against the control in a second stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20047003.001).
  • [ISSN] 0167-9473
  • [Journal-full-title] Computational statistics & data analysis
  • [ISO-abbreviation] Comput Stat Data Anal
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / MH045156-189002; United States / NCI NIH HHS / CA / U10 CA037517
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] Netherlands
  •  go-up   go-down


17. Velenik V, Anderluh F, Oblak I, Strojan P, Zakotnik B: Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J; 2006 Oct;47(5):693-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
  • AIM: To evaluate the efficacy and toxicity of preoperative chemoradiotherapy with capecitabine in locally advanced rectal cancer.
  • METHODS: Between June 2004 and January 2005, 57 patients with operable, clinical stage II-III adenocarcinoma of the rectum entered the prospective phase II study.
  • Total sphincter preservation rate was 65.5% (36 out of 55 patients) and the rate in 27 patients with tumors located within 5 cm of the anal opening was 37% (10 out of 27 patients).

  • Genetic Alliance. consumer health - Rectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):291-7 [10755317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53 [15913913.001]
  • [Cites] Bioorg Med Chem. 2000 Jul;8(7):1697-706 [10976516.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):597-604 [11290435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):675-9 [12062611.001]
  • [Cites] Lancet Oncol. 2002 Jul;3(7):415-24 [12142171.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):403-8 [12243814.001]
  • [Cites] Clin Ther. 2004 Apr;26(4):579-89 [15189755.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):110-5 [8996131.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 18):S18-8-S18-18 [9420016.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):301-8 [9440757.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):543-9; discussion 549-51 [9593234.001]
  • [Cites] Biochem Pharmacol. 1998 Apr 1;55(7):1091-7 [9605432.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 [10758303.001]
  • (PMID = 17042060.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2080466
  •  go-up   go-down


18. Zamboni BA, Yothers G, Choi M, Fuller CD, Dignam JJ, Raich PC, Thomas CR Jr, O'Connell MJ, Wolmark N, Wang SJ: Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol; 2010 May 20;28(15):2544-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07.
  • PURPOSE: Colon cancer overall survival (OS) is usually computed from the time of diagnosis.
  • We extend the concept of CS to condition on the set of patients alive, recurrence-free, and second primary cancer-free (disease-free survival [OS|DFS]).
  • PATIENTS AND METHODS: Using data from National Surgical Adjuvant Breast and Bowel Project trials C-03 through C-07, 5-year OS|DFS was calculated on patients who were disease free up to 5 years after diagnosis, stratified by age, stage, nodal status, and performance status (PS).
  • RESULTS: For stage II, OS|DFS improved from 87% to 92% at 5 years.
  • For stage III, OS|DFS improved from 69% to 88%.
  • CONCLUSION: Prognosis improves over time for almost all groups of patients with colon cancer, especially those with positive nodes.
  • [MeSH-minor] Age Factors. Aged. Clinical Trials, Phase III as Topic. Disease-Free Survival. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Middle Aged. Prognosis. Quality Assurance, Health Care / methods. Randomized Controlled Trials as Topic. United States / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] Lifetime Data Anal. 2008 Dec;14(4):447-63 [18836831.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2211-9 [11596040.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3035-40 [12915592.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):402-6; discussion 406 [14572960.001]
  • [Cites] Oncologist. 2003;8(6):541-52 [14657533.001]
  • [Cites] Eur J Cancer. 2004 May;40(8):1233-43 [15110888.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Semin Surg Oncol. 1994 Jan-Feb;10(1):2-6 [8115782.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):237-42 [8625098.001]
  • [Cites] J Clin Epidemiol. 1997 Nov;50(11):1289-96 [9393385.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1097-106 [9749492.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 2;90(23):1810-6 [9839521.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):485-91 [10023719.001]
  • [Cites] Breast Cancer Res Treat. 1998;51(3):239-53 [10068082.001]
  • [Cites] Chest. 1999 Sep;116(3):697-703 [10492274.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8664-70 [16260700.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2059-64 [16648506.001]
  • [Cites] Cancer. 2006 May 15;106(10):2165-70 [16586498.001]
  • [Cites] Oncologist. 2006 Jun;11(6):624-9 [16794241.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1331-43 [17326199.001]
  • [Cites] J Thorac Oncol. 2007 Mar;2(3):180-90 [17410040.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2198-204 [17470851.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1408-13 [17693654.001]
  • [Cites] Gastric Cancer. 2007;10(3):153-8 [17922092.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):203-9 [18329082.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):257-64 [11263506.001]
  • (PMID = 20406942.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA-69974; United States / NCI NIH HHS / CA / U10 CA012027; United States / NCI NIH HHS / CA / U10 CA069651; United States / NCI NIH HHS / CA / U10CA-37377; United States / NCI NIH HHS / CA / U10 CA069974; United States / NCI NIH HHS / CA / U10CA-12027; United States / NCI NIH HHS / CA / U10 CA037377; United States / NCI NIH HHS / CA / U10CA-69651
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2881729
  •  go-up   go-down


19. Prete F, Prete FP, Nitti P, De Luca R, Vincenti L: [Evolution of surgery for cancer of the anorectal junction]. Chir Ital; 2007 Nov-Dec;59(6):763-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evolution of surgery for cancer of the anorectal junction].
  • [Transliterated title] Evoluzione chirurgica per i tumori del giunto ano-rettale.
  • Certain aspects of the epidemiology, classification and therapy of adenocarcinoma of the anorectal junction (< 5 cm from the anal verge) are not well standardised to date.
  • Intersphincteric resections were performed in 51 males and 33 females, mean age 62, with the following clinical stages: 28 stage 1, 55 stages II and III, 1 stage IV; radiotherapy was administered preoperatively to 27 patients and postoperatively to 18.
  • Assessment of anal sphincter function recovery one year after restoration of bowel continuity showed good continence in 76% of the patients; 2 patients have a permanent ostomy.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360980.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


20. Fallai C, Cerrotta A, Valvo F, Badii D, Olmi P: Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy. Crit Rev Oncol Hematol; 2007 Mar;61(3):261-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy.
  • PURPOSE: To analyse the results achieved with radio-chemotherapy (RTCT) or radiotherapy alone (RT) in elderly patients (pts) affected with squamous cell anal cancer.
  • There were 9 stage I, 29 stage II, 11 stage IIIa and 13 stage IIIb.
  • RESULTS: Stage II fared significantly better than stage III in terms of locoregional control (LRC) but not overall survival (OS).
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085056.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


21. Endreseth BH, Myrvold HE, Romundstad P, Hestvik UE, Bjerkeset T, Wibe A, Norwegian Rectal Cancer Group: Transanal excision vs. major surgery for T1 rectal cancer. Dis Colon Rectum; 2005 Jul;48(7):1380-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal excision vs. major surgery for T1 rectal cancer.
  • PURPOSE: The purpose of this national study was to examine the long-term results of transanal excision compared with major surgery of T1 rectal cancer.
  • METHODS: This prospective study from the Norwegian Rectal Cancer Project included all 291 patients with a T1M0 tumor within 15 cm from the anal verge treated by anterior resection, abdominoperineal resection, Hartmann's procedure, or transanal excision in the period from November 1993 to December 1999.
  • There were no significant differences according to tumor localization, size, or differentiation between Stage I and Stage III tumors.
  • CONCLUSIONS: The main problem of transanal excision for early rectal cancer in the present study was the inability to remove all the malignancy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Proportional Hazards Models. Prospective Studies. Statistics, Nonparametric. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906120.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Pucciarelli S, Capirci C, Emanuele U, Toppan P, Friso ML, Pennelli GM, Crepaldi G, Pasetto L, Nitti D, Lise M: Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol; 2005 Feb;12(2):111-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer.
  • BACKGROUND: We investigated the relationship between pathologic T-stage and mesorectal metastases after preoperative chemoradiotherapy (CRT) for clinical stage II to III rectal carcinoma.
  • METHODS: The records of consecutive patients with clinical stage II to III carcinoma of the mid or low rectum who underwent surgery after CRT were reviewed.
  • Indications for preoperative CRT were cancer up to 11 cm from the anal verge, Eastern Cooperative Oncology Group performance status of 0 to 2, age 18 to 75 years, and clinical tumor-node-metastasis stage II or III.
  • The pretreatment tumor-node-metastasis stage was as follows: I, n = 1; II, n = 96; and III, n = 138.
  • According to the pT stage, the rate of node positivity was 2% for pT0, 15% for pT1, 17% for pT2, 38% for pT3, and 33% for pT4 cases.
  • On considering pT stage alone, the odds ratio was in the region of 10 for pT1/2 and >20 for pT3/4 patients.
  • CONCLUSIONS: In patients with pT0 after preoperative CRT for clinical stage II to III mid or low rectal cancer, the risk of nodal metastases is very low.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2005 Feb;12(2):95-7 [15827785.001]
  • (PMID = 15827790.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Vini L: Neoadjuvant radiochemotherapy for rectal cancer. Dig Dis; 2007;25(1):56-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant radiochemotherapy for rectal cancer.
  • During the past few decades, significant progress has been achieved in the management of rectal cancer with the introduction of total mesorectal excision.
  • Several recent studies show that 5-FU-based chemotherapy enhances tumor response to radiotherapy and preoperative chemoradiotherapy is being increasingly used for stage II and III disease.
  • [MeSH-minor] Anal Canal. Combined Modality Therapy. Humans. Preoperative Care. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17384509.001).
  • [ISSN] 0257-2753
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


24. Serra-Aracil X, Vallverdú H, Bombardó-Junca J, Pericay-Pijaume C, Urgellés-Bosch J, Navarro-Soto S: Long-term follow-up of local rectal cancer surgery by transanal endoscopic microsurgery. World J Surg; 2008 Jun;32(6):1162-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of local rectal cancer surgery by transanal endoscopic microsurgery.
  • BACKGROUND: In 1997 we launched a prospective program of transanal endoscopic microsurgery (TEM) for the treatment of rectal cancer.
  • (III) adenocarcinomas uT2- uN0, low histological grade with intention to cure; and (IV) advanced stage adenocarcinomas with palliative care RESULTS: Transanal endoscopic microsurgery was performed in 218 patients: 122 adenomas, and 96 adenocarcinomas: group II-72, group III-19, and group IV-5.
  • Nine were lost to follow-up, and so 52 patients were studied: group II-38, group III-11, and group IV-3.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Female. Follow-Up Studies. Humans. Male. Microsurgery. Middle Aged. Prospective Studies. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):429-37 [15747069.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1182-92 [15793641.001]
  • [Cites] Am J Surg. 2000 Dec;180(6):402-5; discussion 405-6 [11182387.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):460-3 [15816457.001]
  • [Cites] Dis Colon Rectum. 1983 Mar;26(3):149-51 [6825519.001]
  • [Cites] Dis Colon Rectum. 1995 Dec;38(12):1286-95 [7497841.001]
  • [Cites] Surg Laparosc Endosc. 1998 Aug;8(4):249-56 [9703594.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Dis Colon Rectum. 1993 Jan;36(1):77-97 [8416784.001]
  • [Cites] Gut. 1977 Dec;18(12):1045-50 [606631.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):260-8 [15273550.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Am J Surg. 1998 May;175(5):360-3 [9600277.001]
  • [Cites] Dis Colon Rectum. 2005 Apr;48(4):711-9; discussion 719-21 [15768186.001]
  • [Cites] Dis Colon Rectum. 1984 Feb;27(2):81-3 [6697834.001]
  • [Cites] Dis Colon Rectum. 1997 Apr;40(4):388-92 [9106685.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Colorectal Dis. 2001 Mar;3(2):122-5 [12791005.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):522-29; discussion 529-30 [12368681.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1170-4 [12209248.001]
  • [Cites] Colorectal Dis. 2004 Nov;6(6):432-7 [15521931.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):345-51 [10714627.001]
  • [Cites] Ann Surg Oncol. 1999 Jul-Aug;6(5):433-41 [10458680.001]
  • [Cites] Dis Colon Rectum. 1994 Jan;37(1):52-7 [8287748.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):63-9; discussion 69-70 [1733375.001]
  • (PMID = 18338206.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Caron J, Mangé A, Guillot B, Solassol J: Highly sensitive detection of melanoma based on serum proteomic profiling. J Cancer Res Clin Oncol; 2009 Sep;135(9):1257-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 108 serum samples from 30 early-stage [American Joint Committee on Cancer (AJCC) stage I or II] and 30 advanced-stage (AJCC stage III or IV) melanoma patients and 48 healthy volunteers were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) utilizing protein chip technology and artificial neural networks.
  • RESULTS: In a first step, a multiprotein classifier was built using a training set of 30 pathologically confirmed melanoma and 24 healthy volunteer serum samples, resulting in good classification accuracy for correct diagnosis and stage classification assignment.
  • Subsequently, our multiprotein classifier was tested in an independent validation set of 30 melanoma and 24 non-cancer serum samples patients, maintained in a good diagnostic accuracy of 98.1% (sensitivity 96.7%, specificity 100%), and 100% stage I/II classification assignment.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 May 5;819(1):59-66 [15797521.001]
  • [Cites] Anal Biochem. 2005 Mar 1;338(1):26-31 [15707932.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):577-83 [11208853.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1891-6 [10561230.001]
  • [Cites] Artif Intell Med. 2004 Oct;32(2):71-83 [15364092.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3467-74 [16052624.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1737-45 [12655531.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5088-93 [16051955.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:317-22 [15251977.001]
  • [Cites] Gynecol Oncol. 2007 Dec;107(3):526-31 [17920110.001]
  • [Cites] Melanoma Res. 2005 Dec;15(6):515-22 [16314737.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):512-8 [15234232.001]
  • [Cites] Expert Rev Proteomics. 2006 Jun;3(3):311-20 [16771703.001]
  • [Cites] J Biopharm Stat. 2002 Feb;12(1):1-19 [12146717.001]
  • [Cites] Curr Opin Mol Ther. 2000 Dec;2(6):643-50 [11249741.001]
  • [Cites] Neural Comput. 1998 Jul 28;10(6):1455-80 [9698353.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):4927-32 [8104688.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Ann Oncol. 2003 Jun;14(6):946-57 [12796034.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):5041-4 [11326664.001]
  • [Cites] Melanoma Res. 2002 Jun;12(3):245-53 [12140381.001]
  • [Cites] Methods Mol Biol. 2008;428:125-40 [18287771.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):3091-8 [8221576.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]
  • (PMID = 19288131.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Proteome
  •  go-up   go-down


26. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL: Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol; 2008 Jul;15(7):1948-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.
  • BACKGROUND: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation.
  • METHODS: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified.
  • Patients were significantly less likely to receive guideline treatment if male, older, black or Hispanic, more severe comorbidities, or Stage I (vs Stage II or III).
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414951.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A: Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol; 2008 Jun;87(3):376-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the impact of FDG-PET in the management of anal cancer.
  • PURPOSE: To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease.
  • METHODS AND MATERIALS: Fifty histopathological anal cancer patients were reviewed between 1996 and 2006.
  • RESULTS: The non-PET staging was Stage I(8), Stage II(18), Stage III(22), and Stage IV(2)s.
  • CONCLUSIONS: Anal cancer is FDG-PET avid.
  • PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453023.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


28. Zou YP, Li WM, Zheng F, Li FC, Huang H, Du JD, Liu HR: Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer. World J Gastroenterol; 2010 Oct 28;16(40):5104-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer.
  • AIM: To evaluate the feasibility, efficacy and safety of intraoperative radiofrequency ablation (RFA) combined with (125)iodine seed implantation for unresectable pancreatic cancer.
  • METHODS: Thirty-two patients (21 males and 11 females) at the age of 68 years (range 48-90 years) with unresectable locally advanced pancreatic cancer admitted to our hospital from January 2006 to May 2008 were enrolled in this study.
  • Diagnosis of pancreatic cancer was made through intraoperative biopsy.
  • The median survival time of patients at stage III was longer than that of those at stage IV (19 mo vs 10 mo, P = 0.0026).
  • CONCLUSION: Intraoperative RFA combined with (125)iodine seed implantation is a feasible and safe procedure for unresectable pancreatic cancer with acceptable minor complications, and can prolong the survival time of patients, especially those at stage III.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Feb 1;97(3):554-60 [12548596.001]
  • [Cites] Breast Cancer. 2003;10(1):4-9 [12525756.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1346-52 [12599244.001]
  • [Cites] Eur J Surg Oncol. 2004 Feb;30(1):85-7 [14736529.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Lancet. 1974 Nov 9;2(7889):1127-31 [4139420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):931-5 [2808054.001]
  • [Cites] Ann Surg. 1990 Aug;212(2):132-9 [1695834.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):305-11 [1587751.001]
  • [Cites] Lifetime Data Anal. 1999;5(1):81-90 [10214004.001]
  • [Cites] Gastrointest Endosc. 1999 Sep;50(3):392-401 [10462663.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Dec;47(6):325-8 [15674746.001]
  • [Cites] Clin Liver Dis. 2005 May;9(2):301-14, viii [15831275.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1281-92 [16001679.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1345-50 [16029791.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Aug;5(4):657-66 [16111466.001]
  • [Cites] Invest Radiol. 2005 Sep;40(9):583-90 [16118551.001]
  • [Cites] Prostate. 2005 Nov 1;65(3):260-7 [16015591.001]
  • [Cites] Eur J Radiol. 2005 Dec;56(3):403-8 [15964164.001]
  • [Cites] JOP. 2006;7(1):1-4 [16407612.001]
  • [Cites] JOP. 2006;7(1):74-8 [16407624.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):485-90 [16615151.001]
  • [Cites] Langenbecks Arch Surg. 2007 Jan;392(1):55-60 [17089173.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):327-34 [17674961.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1224-30 [18381371.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5513-8 [19858379.001]
  • [Cites] Pancreas. 2000 Jan;20(1):14-20 [10630378.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Arch Surg. 2000 Mar;135(3):332-5 [10722037.001]
  • [Cites] Acta Chir Iugosl. 2002;49(3):19-24 [12587443.001]
  • (PMID = 20976848.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Other-IDs] NLM/ PMC2965288
  •  go-up   go-down


29. Suzuki A, Kawamoto S, Inada K, Yamamoto N, Kojima T, Nagao S, Ochiai R: [A resected case of bleeding rectal cancer for Jehovah's Witness enabled with preceding colostomy and chemoradiation]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2079-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A resected case of bleeding rectal cancer for Jehovah's Witness enabled with preceding colostomy and chemoradiation].
  • A 66-year-old woman, complaining of anal bleeding with anemia, was examined and diagnosed as advanced rectal cancer.
  • Pathological findings showed moderately differentiated adenocarcinoma with Stage III a.
  • The patient has survived for 31 months with no recurrence, which indicates that preceded colostomy and preoperative chemoradiation enabled a curative resection safely for the Jehovah's Witness patient with bleeding advanced rectal cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037329.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Takashima A, Shimada Y, Hamaguchi T, Ito Y, Masaki T, Yamaguchi S, Kondo Y, Saito N, Kato T, Ohue M, Higashino M, Moriya Y, Colorectal Cancer Study Group of the Japan Clinical Oncology Group: Current therapeutic strategies for anal squamous cell carcinoma in Japan. Int J Clin Oncol; 2009 Oct;14(5):416-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current therapeutic strategies for anal squamous cell carcinoma in Japan.
  • BACKGROUND: In Western countries, chemoradiotherapy (CRT) is well established as the standard therapy for stages II/III anal squamous cell carcinoma (ASCC).
  • The Colorectal Cancer Study Group of the Japan Clinical Oncology Group (JCOG-CCSG) conducted a survey to determine the current therapeutic strategies for ASCC in Japan.
  • The target subjects were patients with stages II/III ASCC, diagnosed from January 2000 to December 2004, who were 20-80 years of age with normal major organ function and no severe complications.
  • Detailed information was obtained for 55 subjects; 25 (45%) had stage II ASCC and 30 (55%) had stage III ASCC.
  • The 3-year progression-free survival rates for all subjects and for CRT-only subjects were 67% and 77%, respectively.
  • [MeSH-major] Anus Neoplasms / therapy. Asian Continental Ancestry Group. Carcinoma, Squamous Cell / therapy. Digestive System Surgical Procedures

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1994 Mar;8(3):283-95 [8031509.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Cancer. 1983 Apr 1;51(7):1291-6 [6825051.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):575-81 [9261527.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):850-6 [2724350.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3121-5 [8955657.001]
  • [Cites] Surg Oncol. 2005 Nov;14(3):121-32 [16165347.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1195-202 [12599225.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):806-10 [2765832.001]
  • (PMID = 19856049.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Investigator] Kondo Y; Ohtsuka K; Shiiba K; Sato T; Yoshimi F; Kotake K; Sawada T; Mochizuki H; Konishi F; Saito N; Moriya Y; Masaki T; Aoki T; Takahashi K; Hasegawa H; Kenichi S; Sumiyama Y; Sato T; Akaike M; Kudo S; Yamada T; Munakata Y; Shigeski Y; Kato T; Maeda K; Koizumi K; Monden M; Ohue M; Higashino M; Tanigawa M; Fukunaga M; Kato T; Okamura S; Kimura H; Okajima M; Takakura N; Tanada M; Shirouzu K; Kitano S
  •  go-up   go-down


31. Garlipp B, Ptok H, Schmidt U, Meyer F, Gastinger I, Lippert H: Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial. Langenbecks Arch Surg; 2010 Nov;395(8):1031-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.
  • INTRODUCTION: Randomized trials have demonstrated a reduction in local recurrence rate in rectal cancer patients treated with preoperative chemoradiotherapy and total mesorectal excision (TME) compared to patients undergoing TME alone.
  • Accordingly, preoperative chemoradiotherapy in all UICC stages II and III rectal cancers has been recommended in the German treatment guidelines as of 2004.
  • It was the aim of our analysis to investigate the influence of preoperative chemoradiotherapy on anastomotic leak rate and postoperative bladder dysfunction in rectal cancer patients using a representative data set from the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.
  • METHOD: This is a retrospective analysis of data from the Quality Assurance in Rectal Cancer Surgery prospective multicenter observational trial.
  • Data of all patients undergoing curatively intended sphincter-preserving resection for UICC stage I through III rectal carcinoma between 01 Jan 2005 and 31 Dec 2007 with or without preoperative chemoradiotherapy (groups A and B, respectively) were included.
  • Significant differences were present between groups regarding age, sex, distance of the tumor from the anal verge, pT-stage, UICC stage, hepatic risk factors, and use of protective enterostomy by univariate analysis.
  • CONCLUSION: Neoadjuvant chemoradiotherapy for rectal carcinoma does not increase the risk for anastomotic leakage or postoperative bladder dysfunction after curatively intended sphincter-preserving rectal resection.
  • [MeSH-major] Anal Canal / surgery. Anastomotic Leak / etiology. Neoadjuvant Therapy. Postoperative Complications / etiology. Quality Assurance, Health Care. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Rectum / surgery. Urinary Bladder Diseases / etiology


32. Jelski W, Mroczko B, Szmitkowski M: The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients. Dig Dis Sci; 2010 Oct;55(10):2953-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients.
  • BACKGROUND: The activity of total alcohol dehydrogenase (ADH) and class I isoenzymes is significantly higher in colorectal cancer tissue than in healthy mucosa.
  • The activity of these enzymes in cancer cells is probably reflected in the sera and could thus be helpful for diagnosing colorectal cancer.
  • AIM: The aim of this study was to investigate a potential role of ADH and aldehyde dehydrogenase (ALDH) as tumor markers for colorectal cancer.
  • METHODS: Serum samples were taken from 182 patients with colorectal cancer before treatment and from 160 control subjects.
  • Total ADH activity and class III and IV isoenzymes were measured by photometric, but ALDH activity and ADH I and II by the fluorometric method, with class-specific fluorogenic substrates.
  • RESULTS: There was significant increase in the activity of ADH I isoenzyme and ADH total in the sera of colorectal cancer patients compared to the control.
  • The sensitivity and specificity of ADH I increased with the stage of the carcinoma.
  • CONCLUSION: The results suggest a potential role for ADH I as marker for colorectal cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 1989 Oct 23;257(1):105-9 [2806555.001]
  • [Cites] Clin Chem. 1993 Nov;39(11 Pt 1):2298-304 [8222224.001]
  • [Cites] Clin Exp Med. 2006 Jun;6(2):89-93 [16820997.001]
  • [Cites] Anal Biochem. 1989 Apr;178(1):57-62 [2729580.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):977-81 [15309886.001]
  • [Cites] Clin Exp Med. 2007 Dec;7(4):154-7 [18188528.001]
  • [Cites] Anal Biochem. 1979 Oct 15;99(1):65-71 [231394.001]
  • [Cites] Dig Dis Sci. 2005 Jun;50(6):1019-24 [15986847.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Aug;16(4):775-810 [12418049.001]
  • [Cites] Digestion. 1996;57(2):105-8 [8785998.001]
  • [Cites] Clin Chem Lab Med. 2008;46(10):1423-8 [18844497.001]
  • [Cites] Clin Chim Acta. 2006 Sep;371(1-2):143-7 [16603145.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):208-12 [17368603.001]
  • [Cites] Alcohol Clin Exp Res. 1996 May;20(3):551-5 [8727253.001]
  • [Cites] Alcohol Clin Exp Res. 1996 Dec;20(9):1569-76 [8986205.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):33-8 [16520929.001]
  • [Cites] Clin Chem Lab Med. 2003 May;41(5):646-51 [12812262.001]
  • [Cites] BMJ. 2000 Feb 12;320(7232):424-7 [10669448.001]
  • (PMID = 20069455.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Isoenzymes; EC 1.1.1.1 / Alcohol Dehydrogenase; EC 1.2.1.3 / Aldehyde Dehydrogenase
  •  go-up   go-down


33. Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients. Int Semin Surg Oncol; 2007 Sep 20;4:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients.
  • METHODS: patients were screened following these eligibility criteria: histology-proven adenocarcinoma of the rectum; distal tumour extent at 12 cm or less from the anal verge; clinical stage T3-4/anyN, or anyT/N1-2; ECOG Performance Status 0-2.
  • Twenty-eight patients were stage II and 19 stage III.
  • CONCLUSION: bifractionated accelerated RT administered in the preoperative setting to patients bearing locally advanced rectal cancer is reliable and safe, as its immediate and late toxicity (mainly infectious) is acceptably low and long-term survivals are achievable.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Am J Surg. 1994 Jan;167(1):90-4; discussion 94-5 [8311145.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):157-67 [9488510.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):633-40 [11685026.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] Ann Surg. 1994 Nov;220(5):676-82 [7979617.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):259-62 [12082685.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):964-8 [8813788.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):67-73 [7826163.001]
  • [Cites] Dis Colon Rectum. 1992 Aug;35(8):757-61 [1643999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 May;10(5):593-8 [6735750.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):5-14 [14704839.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):387-92 [1587760.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Clin Radiol. 1971 Apr;22(2):145-55 [5575251.001]
  • (PMID = 17883838.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2063497
  •  go-up   go-down


34. Deschoolmeester V, Baay M, Wuyts W, Van Marck E, Pelckmans P, Lardon F, Vermorken JB: Comparison of three commonly used PCR-based techniques to analyze MSI status in sporadic colorectal cancer. J Clin Lab Anal; 2006;20(2):52-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of three commonly used PCR-based techniques to analyze MSI status in sporadic colorectal cancer.
  • Several retrospective studies have shown that a high level of microsatellite instability (MSI-H) is an important prognostic factor of a more favorable outcome in stage II and III colorectal cancer (CRC) patients.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16538640.001).
  • [ISSN] 0887-8013
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


35. Hohenberger W, Merkel S, Matzel K, Bittorf B, Papadopoulos T, Göhl J: The influence of abdomino-peranal (intersphincteric) resection of lower third rectal carcinoma on the rates of sphincter preservation and locoregional recurrence. Colorectal Dis; 2006 Jan;8(1):23-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of abdomino-peranal (intersphincteric) resection of lower third rectal carcinoma on the rates of sphincter preservation and locoregional recurrence.
  • PATIENTS AND METHODS: The data of 476 patients with a carcinoma in the lower third of the rectum who underwent primary treatment for stage I-III disease by low anterior resection, abdomino-peranal (intersphincteric) resection or abdominoperineal excision between 1985 and 2001 were analysed.
  • The cancer-related 5-year survival rate was not altered by intersphincteric resection.
  • [MeSH-major] Anal Canal / surgery. Carcinoma / surgery. Colectomy / methods. Neoplasm Recurrence, Local / epidemiology. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519634.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Velenik V, Ocvirk J, Oblak I, Anderluh F: A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol; 2010 Mar;36(3):244-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
  • BACKGROUND: Neoadjuvant chemoradiotherapy (CRT) reduces local tumor recurrence in locally advanced rectal cancer (LARC).
  • METHODS: Patients with stage II/III LARC received capecitabine 1250 mg/m(2) twice daily for 2 weeks followed by intravenous cetuximab 400 mg/m(2) at week 3, then weekly intravenous 250 mg/m(2) cetuximab plus CRT including capecitabine 825 mg/m(2) twice daily (including weekends during radiotherapy) with radiotherapy of 45 Gy (25 x 1.8 Gy), 5 days a week for 5 weeks.
  • Total sphincter preservation rate was 76%, and 53% in 17 patients whose tumors were located within 5 cm from the anal verge.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20042310.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Prodrugs; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil
  •  go-up   go-down


37. Loredo-Pozos G, Chiquete E, Oceguera-Villanueva A, Panduro A, Siller-López F, Ramos-Márquez ME: Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates. Med Oncol; 2009;26(3):269-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates.
  • Low BRCA1 gene expression is associated with increased invasiveness and influences the response of breast carcinoma (BC) to chemotherapeutics.
  • Women aged < or = 35 years (24%) had more family history of cervical cancer, stage III/IV disease, HER-2 positivity, and lower BRCA1 expression than older women (P < 0.05).
  • After multivariate analysis, only disease stage explained BRCA1 mRNA levels in the lowest quartile.
  • Low BRCA1 mRNA expression is associated mainly with younger ages and advanced clinical stage of premenopausal BC.


38. Li SY, Liang ZJ, Yuan SJ, Yu B, Chen G, Zuo FY, Bai X, Chen G, Wei XJ, Xu YS, Cui W: [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Apr;13(4):263-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer].
  • OBJECTIVE: To evaluate the clinical efficacy, feasibility and safety of sphincter-preservation with telescopic anastomosis of colon and rectal mucosa in low-middle rectal cancer.
  • METHODS: A retrospective analysis was carried out in 371 patients with low-middle rectal cancer in whom telescopic anastomosis was used.
  • The lower margins of the tumors located between 5-8 cm from the anal verge.
  • According to the Duke's stage classification, 120 were TNM stage I, 222 stage II, 26 stage III, and 3 stage IV.
  • CONCLUSION: The sphincter-preservation with telescopic anastomosis procedure is safe and effective for low-middle rectal cancer, and the sphincter function can be well-preserved.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Anastomosis, Surgical / methods. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422480.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


39. Weiser MR, Quah HM, Shia J, Guillem JG, Paty PB, Temple LK, Goodman KA, Minsky BD, Wong WD: Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. Ann Surg; 2009 Feb;249(2):236-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection.
  • OBJECTIVE: The aim of this study was to evaluate oncologic outcome in patients with locally advanced distal rectal cancer treated with preoperative chemoradiation followed by low anterior resection (LAR)/stapled coloanal anastomosis, LAR/intersphincteric dissection/hand-sewn coloanal anastomosis, or abdominoperineal resection (APR).
  • SUMMARY BACKGROUND DATA: Distal rectal cancer presents a surgical challenge, and the goals of treatment often include tumor eradication without sacrifice of the anal sphincters.
  • The technique of intersphincteric resection removes the internal anal sphincter to gain additional distal rectal margin in hopes of avoiding a permanent stoma.
  • METHODS: We analyzed 148 patients with stage II and III rectal cancers (endorectal ultrasound staged uT3-4 and/or uN1) located < or =6 cm from the anal verge, treated by preoperative chemoradiation and total mesorectal excision from 1998 to 2004.
  • CONCLUSIONS: In low rectal cancer, sphincter preservation is facilitated by a significant response to preoperative chemoradiation and intersphincteric resection, without compromise of margins or outcome.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / physiopathology. Anal Canal / surgery. Antineoplastic Agents / administration & dosage. Colectomy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212176.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


40. Gervaz P, Lavertu S, Kazemba B, Pemberton JH, Haddock MG, Gunderson LL: Sphincter-preserving radiation therapy for rectal cancer: a simulation study using three-dimensional computerized technology. Colorectal Dis; 2006 Sep;8(7):570-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphincter-preserving radiation therapy for rectal cancer: a simulation study using three-dimensional computerized technology.
  • This approach provides, in theory, a means to selectively subtract the anal sphincter from the high-dose field of irradiation in patients with stage II and III adenocarcinomas of the mid-rectum scheduled for low anterior resection (LAR).
  • HYPOTHESIS: Implementation of 3DXRT with sphincter blocking may be a feasible strategy to reduce the dose of radiation distributed to the anal canal without reduction in the dose distribution to the gross tumour volume (GTV) plus adequate margins.
  • METHODS: Pretreatment simulation CT scans of 10 patients with rectal cancers located between 5 and 10 cm from the anal verge were retrieved from a computerized database.
  • Radiation oncologists and colorectal surgeons defined the contours of the GTV and the anal sphincter, respectively, on successive CT scan slices.
  • RESULTS: The mean distance of tumours from the anal verge was 6.3 cm.
  • The mean volume of the anal sphincter was 16.1 +/- 3.5 cm(3).
  • By comparison the mean dose distributed to the anal sphincter was dramatically reduced by using a sphincter block (33.2 +/- 12 Gy vs 6.4 +/- 4.1 Gy, P < 0.001).
  • CONCLUSION: During a course of radiotherapy for most low- or mid-rectal cancers, the anal canal is included within the field of irradiation with a mean dose distribution to the sphincter of 33 Gy.
  • Evaluation of 3DXRT with full sphincter block (mid-rectum) and partial sphincter block (distal rectum) is a feasible strategy to decrease the volume of anal sphincter carried to full dose without reduction in dose to the GTV.
  • This approach, by minimizing treatment-induced damage to the anal sphincter, might improve functional outcome of LAR.
  • [MeSH-major] Anal Canal / radiation effects. Computer Simulation. Radiotherapy Planning, Computer-Assisted. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919108.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


41. de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, de Jong S, van der Zee AG: The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer; 2008 Jul 22;99(2):341-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer.
  • Ovarian cancer is the most frequent cause of death from gynaecological cancer in the Western world.
  • Current prognostic factors do not allow reliable prediction of response to chemotherapy and survival for individual ovarian cancer patients.
  • Epidermal growth factor receptor (EGFR) and HER-2/neu are frequently expressed in ovarian cancer but their prognostic value remains unclear.
  • In this study, we investigated the expression and prognostic value of EGFR, EGFR variant III (EGFRvIII), HER-2/neu and important downstream signalling components in a large series of epithelial ovarian cancer patients.
  • Our results show that negative PTEN immunostaining was associated with stage I/II disease (P=0.006), non-serous tumour type (P=0.042) and in multivariate analysis with a longer progression-free survival (P=0.015).
  • Negative PTEN staining also predicted improved progression-free survival in patients with grade III or undifferentiated serous carcinomas (P=0.011).
  • Positive pAKT staining was associated with advanced-stage disease (P=0.006).


42. Singer M, Mutch MG: Anal melanoma. Clin Colon Rectal Surg; 2006 May;19(2):78-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal melanoma.
  • Anal melanoma is rare and aggressive malignancy.
  • Unlike cutaneous melanoma, anal melanoma has no known risk factors.
  • There are no long-term survivors of stage II or III disease; therefore, early diagnosis and treatment remain crucial.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Apr 29;340(17):1341-8 [10219070.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1203-8 [10496563.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):453-63; discussion 463-5 [10522715.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]
  • [Cites] Oncology (Williston Park). 1999 Nov;13(11):1561-74; discussion 1574 passim [10581603.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):863-7 [10741708.001]
  • [Cites] Recent Results Cancer Res. 2000;157:178-89 [10857171.001]
  • [Cites] Curr Oncol Rep. 2000 Jul;2(4):292-9 [11122856.001]
  • [Cites] Chir Ital. 2000 Jul-Aug;52(4):329-34 [11190522.001]
  • [Cites] South Med J. 2001 Sep;94(9):880-5 [11592745.001]
  • [Cites] Tech Coloproctol. 2001 Apr;5(1):51-4 [11793262.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1818-25 [11919239.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):964-72 [11958890.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):438-48; discussion 448-9 [12368672.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4555-8 [12454112.001]
  • [Cites] Melanoma Res. 2002 Aug;12(4):395-8 [12170190.001]
  • [Cites] Hepatogastroenterology. 2002 Nov-Dec;49(48):1545-8 [12397731.001]
  • [Cites] Histopathology. 2002 Dec;41(6):519-25 [12460204.001]
  • [Cites] Int J Gastrointest Cancer. 2002;32(1):53-6 [12630771.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2019-22 [14647131.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1478-83 [15042682.001]
  • [Cites] Radiology. 2004 Jul;232(1):181-6 [15220501.001]
  • [Cites] Anticancer Drugs. 2005 Mar;16(3):345-8 [15711188.001]
  • [Cites] J Clin Pathol. 1963 Mar;16(2):126-32 [16811001.001]
  • [Cites] Int Surg. 1980 Sep-Oct;65(5):423-6 [7451062.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 15;87(22):1710-3 [7473820.001]
  • [Cites] J Surg Oncol. 1995 Feb;58(2):118-20 [7844981.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]
  • [Cites] Ann N Y Acad Sci. 1993 Aug 12;690:167-77 [8368735.001]
  • [Cites] Int J Colorectal Dis. 1993 Jul;8(2):81-6 [8409692.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):174-8 [8419240.001]
  • [Cites] Histopathology. 1993 Mar;22(3):261-4 [8495957.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):88-94 [10618610.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):87-97 [10761786.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):680-4 [11034246.001]
  • [Cites] Surg Today. 2001;31(6):527-9 [11428607.001]
  • [Cites] Surg Oncol. 2001 Jul-Aug;10(1-2):53-9 [11719029.001]
  • [Cites] Br J Surg. 2002 Apr;89(4):389-96 [11952577.001]
  • [Cites] J Am Coll Surg. 2003 Feb;196(2):206-11 [12595048.001]
  • [Cites] Can J Surg. 2003 Oct;46(5):345-9 [14577706.001]
  • [Cites] Melanoma Res. 2004 Apr;14(2):147-50 [15057046.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1183-7 [15449271.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):446-9 [15820458.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):874-7 [1698595.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):729-35 [2016615.001]
  • [Cites] Surgery. 1990 Jan;107(1):1-9 [2296748.001]
  • [Cites] Arch Surg. 1990 Mar;125(3):313-6 [2306178.001]
  • [Cites] Radiother Oncol. 1989 Nov;16(3):169-82 [2587808.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1364-70 [3345491.001]
  • [Cites] Br J Surg. 1986 Jan;73(1):68-9 [3947881.001]
  • [Cites] Acta Chir Scand. 1974;140(1):68-72 [4819025.001]
  • [Cites] CA Cancer J Clin. 1966 May-Jun;16(3):111-4 [4957071.001]
  • [Cites] Dis Colon Rectum. 1967 May-Jun;10(3):161-76 [6026797.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1299-305 [6362841.001]
  • [Cites] Am J Surg. 1983 Sep;146(3):336-8 [6614323.001]
  • [Cites] N Engl J Med. 1982 Oct 7;307(15):913-6 [7050717.001]
  • [Cites] Surg Gynecol Obstet. 1982 Mar;154(3):337-41 [7064068.001]
  • [Cites] Dis Colon Rectum. 1982 Oct;25(7):693-703 [7128372.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):772-7 [7172945.001]
  • [Cites] Br J Surg. 1981 Sep;68(9):667-8 [7272698.001]
  • [Cites] Dis Colon Rectum. 1980 Mar;23(2):122-4 [7379659.001]
  • [Cites] Arch Surg. 1996 Sep;131(9):975-9; 979-80 [8790168.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):255-63; discussion 263-6 [8813254.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):827-35 [8922197.001]
  • [Cites] Eur J Surg Oncol. 1996 Dec;22(6):598-601 [9005147.001]
  • [Cites] Surg Oncol. 1996 Aug;5(4):165-8 [9067564.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Mar;16(1):81-5 [9148866.001]
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] Surg Today. 1997;27(8):753-6 [9306593.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):69-77; discussion 77-9 [9660028.001]
  • [Cites] Eur J Surg Oncol. 1998 Aug;24(4):303-7 [9724998.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2921-9 [9738559.001]
  • [Cites] Cancer. 1998 Oct 15;83(8):1664-78 [9781962.001]
  • [Cites] Acta Oncol. 1998;37(5):497-9 [9831382.001]
  • [Cites] Eur J Cancer. 1998 Jul;34 Suppl 3:S22-6 [9849405.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 16;90(24):1894-900 [9862627.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):476-80 [9887254.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):976-83 [10071292.001]
  • (PMID = 20011314.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780102
  • [Keywords] NOTNLM ; Melanoma / abdominoperineal resection / anal / malignancy / wide local excision
  •  go-up   go-down


43. Habr-Gama A, Perez RO, Nadalin W, Nahas SC, Ribeiro U Jr, Silva E Sousa AH Jr, Campos FG, Kiss DR, Gama-Rodrigues J: Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg; 2005 Jan;9(1):90-9; discussion 99-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
  • Neoadjuvant chemoradiation treatment (CRT) has resulted in significant tumor downstaging and improved local disease control for distal rectal cancer.
  • The purpose of the present study was to determine the correlation between final stage and survival in these patients regardless of initial disease stage.
  • Two hundred sixty patients with distal (0-7 cm from anal verge) rectal adenocarcinoma considered resectable were treated by neoadjuvant CRT with 5-FU and leucovorin plus 5040 cGy.
  • Overall survival and disease-free survival were compared according to Kaplan-Meier curves and log-rank tests according to final stage.
  • Seventy-one patients (28%) showed complete clinical response (clinical stage 0).
  • In 22 of these patients (9%), pathologic examination revealed pT0 N0 M0 (stage p0), 59 patients (22%) had stage I, 68 patients (26%) had stage II, and 40 patients (15%) had stage III disease.
  • Overall survival rates were significantly higher in stage c0 (P=0.01) compared with stage p0.
  • Disease-free survival rate showed better results in stage c0, but the results were not significant.
  • Five-year overall and disease-free survival rates were 97.7% and 84% (stage 0); 94% and 74% (stage I); 83% and 50% (stage II); and 56% and 28% (stage III), respectively.
  • Cancer-related overall and disease-free survival may be correlated to final pathologic staging following neoadjuvant CRT for distal rectal cancer.
  • Also, stage 0 is significantly associated with improved outcome.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):999-1003 [12905555.001]
  • [Cites] J Gastrointest Surg. 2004 Jan;8(1):56-62; discussion 62-3 [14746836.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1027-38 [10421535.001]
  • [Cites] Eur J Surg Oncol. 2001 Jun;27(4):349-53 [11417978.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Rev Invest Clin. 2001 Sep-Oct;53(5):388-95 [11795103.001]
  • [Cites] J Natl Cancer Inst. 1988 Mar 2;80(1):21-9 [3276900.001]
  • [Cites] Rev Invest Clin. 2001 Jan-Feb;53(1):65-76 [11332053.001]
  • [Cites] Br J Surg. 2001 Jul;88(7):988-93 [11442533.001]
  • [Cites] World J Surg. 2001 Aug;25(8):1006-11 [11571965.001]
  • [Cites] Br J Surg. 1986 Sep;73(9):732-5 [3756437.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1121-30 [11920483.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):935-41 [9869213.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1417-24 [7751887.001]
  • [Cites] Dis Colon Rectum. 1997 May;40(5):515-22 [9152176.001]
  • [Cites] Dis Colon Rectum. 2001 Aug;44(8):1123-8 [11535851.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1695-1701; discussion 1701-3 [11156453.001]
  • [Cites] Radiother Oncol. 1999 May;51(2):153-60 [10435807.001]
  • [Cites] J Surg Oncol. 2003 Jul;83(3):133-9 [12827680.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):206-10 [11822961.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):563-9 [7507795.001]
  • [Cites] J Am Coll Surg. 2002 Feb;194(2):131-5; discussion 135-6 [11848629.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):279-86 [14991488.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1087-96 [9749491.001]
  • [Cites] J Pathol. 1994 Feb;172(2):183-7 [7513353.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):21-7 [9588913.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]
  • (PMID = 15623449.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


44. Natarajan L, Pu M, Parker BA, Thomson CA, Caan BJ, Flatt SW, Madlensky L, Hajek RA, Al-Delaimy WK, Saquib N, Gold EB, Pierce JP: Time-varying effects of prognostic factors associated with disease-free survival in breast cancer. Am J Epidemiol; 2009 Jun 15;169(12):1463-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time-varying effects of prognostic factors associated with disease-free survival in breast cancer.
  • Early detection and effective treatments have dramatically improved breast cancer survivorship, yet the risk of relapse persists even 15 years after the initial diagnosis.
  • It is important to identify prognostic factors for late breast cancer events.
  • The authors investigated time-varying effects of tumor characteristics on breast-cancer-free survival using data on 3,088 breast cancer survivors from 4 US states who participated in a randomized dietary intervention trial in 1995-2006, with maximum follow-up through 15 years (median, 9 years).
  • Having a stage II or III tumor was associated with a 3-fold higher hazard of breast cancer than having a stage I tumor during the first 2.5 years after diagnosis; this hazard ratio decreased to 2.1 after 7.7 years, but higher tumor stage remained a significant risk factor.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Radiat Oncol. 2002 Oct;12(4):319-28 [12382190.001]
  • [Cites] JAMA. 2007 Jul 18;298(3):289-98 [17635889.001]
  • [Cites] Breast Cancer Res Treat. 2003 Mar;78(1):105-18 [12611463.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1331-6 [15042664.001]
  • [Cites] Biometrics. 2004 Jun;60(2):344-51 [15180659.001]
  • [Cites] Biometrics. 1989 Mar;45(1):135-44 [2720049.001]
  • [Cites] Lifetime Data Anal. 1997;3(1):13-25 [9384623.001]
  • [Cites] Breast Cancer Res Treat. 1998;52(1-3):227-37 [10066085.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] JAMA. 2006 Apr 12;295(14):1658-67 [16609087.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Stat Med. 2006 Aug 30;25(16):2831-45 [16158396.001]
  • [Cites] Biom J. 2007 Jun;49(3):453-73 [17623349.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4168-74 [18593996.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83 [18695137.001]
  • [Cites] Breast Cancer Res Treat. 2009 Aug;116(3):595-602 [18830816.001]
  • [Cites] Control Clin Trials. 2002 Dec;23(6):728-56 [12505249.001]
  • (PMID = 19403844.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA069375-09; United States / NCI NIH HHS / CA / R01 CA069375-06S1; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCI NIH HHS / CA / R01 CA069375-04S3; United States / NCI NIH HHS / CA / R01 CA069375-04S4; United States / NCI NIH HHS / CA / R01 CA069375-05S5; United States / NCRR NIH HHS / RR / M01-RR00827; United States / NCI NIH HHS / CA / R01 CA069375-06S2; United States / NCI NIH HHS / CA / R01 CA069375-05S1; United States / NCI NIH HHS / CA / R01 CA069375-03S1; United States / NCI NIH HHS / CA / CA 69375; United States / NCI NIH HHS / CA / R01 CA069375-04S2; United States / NCI NIH HHS / CA / R01 CA069375-08; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / R01 CA069375-04; United States / NCI NIH HHS / CA / R01 CA069375-05; United States / NCI NIH HHS / CA / R01 CA069375-02; United States / NCI NIH HHS / CA / CA069375-08; United States / NCRR NIH HHS / RR / M01-RR00070; United States / NCI NIH HHS / CA / R01 CA069375-06; United States / NCI NIH HHS / CA / R01 CA069375-10; United States / NCI NIH HHS / CA / R01 CA069375-05S4; United States / NCI NIH HHS / CA / R01 CA069375-03; United States / NCI NIH HHS / CA / R01 CA069375-07; United States / NCI NIH HHS / CA / R01 CA069375-05S2; United States / NCRR NIH HHS / RR / M01 RR000070; United States / NCI NIH HHS / CA / R01 CA069375-04S1; United States / NCRR NIH HHS / RR / M01 RR000827; United States / NCI NIH HHS / CA / R01 CA069375-02S1; United States / NCI NIH HHS / CA / R01 CA069375; United States / NCI NIH HHS / CA / R01 CA069375-05S3
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2733768
  •  go-up   go-down


45. Hessien MH, El-Sharkawi IM, El-Barbary AA, El-Beltagy DM, Snyder N: Non-invasive index of liver fibrosis induced by alcohol, thioacetamide and Schistosomal infection in mice. BMC Gastroenterol; 2010;10:53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The following methods were employed: (i) The METAVIR system was utilized to grade and stage liver inflammation and fibosis;.
  • (ii) Determination of hepatic hydroxyproline and collagen; and (iii) Derivation of a new hepatic fibrosis index from the induced changes, and its prospective validation in a group of 70 mice.
  • These parameters were highly correlated with both the histological stage and the grade.
  • They were combined in a logarithmic formula, which non-invasively scores the severity of liver fibrosis through a range (0 to 2), starting with healthy liver (corresponding to stage 0) to advanced fibrosis (corresponding stage 3).Receiver operating characteristic curves (ROC) for the accuracy of the index to predict the histological stages demonstrated that the areas under the curve (AUC) were 0.954, 0.979 and 0.99 for index values corresponding to histological stages 1, 2 and 3, respectively.
  • Also, the index was correlated with stage and grade, (0.947 and 0.859, respectively).
  • The AUROC was 0.869 and there was good correlation with the stage of fibrosis and grade of inflammation.

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • Hazardous Substances Data Bank. THIOACETAMIDE .
  • Hazardous Substances Data Bank. ETHANOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1999 Dec;30(6):1529-30 [10610352.001]
  • [Cites] Hepatology. 2009 Jun;49(6):1821-7 [19291784.001]
  • [Cites] N Engl J Med. 2001 Feb 15;344(7):495-500 [11172192.001]
  • [Cites] Lancet. 2001 Apr 7;357(9262):1069-75 [11297957.001]
  • [Cites] Hum Exp Toxicol. 2001 May;20(5):251-4 [11476157.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):986-92 [12297848.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2614-8 [12385448.001]
  • [Cites] Hepatology. 1997 Dec;26(6):1393-8 [9397976.001]
  • [Cites] Hepatology. 1999 Jan;29(1):14-20 [9862843.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):222-30 [12873819.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):239-44 [12873821.001]
  • [Cites] Hepatology. 2003 Aug;38(2):518-26 [12883497.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2003 Feb;2(1):69-72 [14607650.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Res Exp Med (Berl). 1980;177(3):201-11 [6449727.001]
  • [Cites] Pharmacol Ther. 1985;29(1):129-56 [3914644.001]
  • [Cites] Pharmacol Toxicol. 1987 Mar;60(3):171-4 [3588511.001]
  • [Cites] Exp Pathol. 1988;34(4):229-36 [2853079.001]
  • [Cites] Hepatology. 1996 Aug;24(2):289-93 [8690394.001]
  • [Cites] Arch Biochem Biophys. 1959 May;82(1):70-7 [13650640.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):343-50 [15685546.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):167-74 [15704051.001]
  • [Cites] Alcohol Clin Exp Res. 2006 Aug;30(8):1429-35 [16899047.001]
  • [Cites] J Hepatol. 2007 May;46(5):775-82 [17321634.001]
  • [Cites] Clin Chim Acta. 2007 Jun;381(2):119-23 [17442291.001]
  • [Cites] Rinsho Byori. 2007 Aug;55(8):751-7 [17882797.001]
  • [Cites] Hepatology. 2008 Feb;47(2):455-60 [18038452.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):2033-42 [18339886.001]
  • [Cites] Chest. 2008 May;133(5):1101-6 [18071010.001]
  • [Cites] Anal Biochem. 2000 Oct 1;285(1):16-20 [10998259.001]
  • (PMID = 20515488.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 075T165X8M / Thioacetamide; 3K9958V90M / Ethanol; 9007-34-5 / Collagen; EC 2.3.2.2 / gamma-Glutamyltransferase; GAN16C9B8O / Glutathione; RFM9X3LJ49 / Bilirubin; RMB44WO89X / Hydroxyproline
  • [Other-IDs] NLM/ PMC2894747
  •  go-up   go-down


46. Kim SH, Park IJ, Joh YG, Hahn KY: Laparoscopic resection for rectal cancer: a prospective analysis of thirty-month follow-up outcomes in 312 patients. Surg Endosc; 2006 Aug;20(8):1197-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic resection for rectal cancer: a prospective analysis of thirty-month follow-up outcomes in 312 patients.
  • BACKGROUND: This study aimed to prospectively evaluate operative safety and mid-term oncologic outcomes of laparoscopic rectal cancer resection performed by a single surgeon.
  • 257 patients (82.4%) had tumors located below 12 cm from the anal verge.
  • Distribution of TNM stages was 0:I:II:III:IV = 4.2%:17.9%:32.4%:37.2%:8.3%.
  • With a mean follow-up of 30 months in the stage I-III patients, the local recurrence rate was 2.9%.
  • CONCLUSION: Laparoscopic resection of rectal cancer provided safe operative parameters and adequate mid-term oncologic outcomes.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Surg Endosc. 2004 Oct;18(10):1457-62 [15791369.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):473-83; discussion 483-6 [11330574.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):260-8 [15273550.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):800-11 [9637543.001]
  • [Cites] Surg Endosc. 2005 Jun;19(6):757-66 [15868256.001]
  • [Cites] Br J Surg. 2001 Nov;88(11):1501-5 [11683749.001]
  • [Cites] Colorectal Dis. 2005 Jul;7(4):403-5 [15932567.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):335-42 [12616116.001]
  • [Cites] Surgery. 1998 Oct;124(4):612-7; discussion 617-8 [9780979.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):544-52; discussion 552-4 [10522724.001]
  • [Cites] Int J Colorectal Dis. 2005 Sep;20(5):428-33 [15800782.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):989-95 [12163970.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1224-6 [7953369.001]
  • [Cites] Surg Gynecol Obstet. 1984 Jan;158(1):33-8 [6691164.001]
  • [Cites] Br J Surg. 2005 Feb;92(2):230-4 [15609379.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):281-9 [14691716.001]
  • (PMID = 16865622.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


47. Ceelen W, Boterberg T, Pattyn P, van Eijkeren M, Gillardin JM, Demetter P, Smeets P, Van Damme N, Monsaert E, Peeters M: Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer. Ann Surg Oncol; 2007 Feb;14(2):424-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer.
  • BACKGROUND: Neoadjuvant therapy is increasingly used in resectable locally advanced rectal cancer.
  • METHODS: Clinical, pathological, and survival data were obtained from patients with resectable stage II or III rectal cancer within 7 cm from the anal verge.
  • The mean distance from the anal verge was 5.8 cm (HART) versus 4.9 cm (CRT).

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096057.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Widder J, Kastenberger R, Fercher E, Schmid R, Langendijk JA, Dobrowsky W, Pötter R: Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol; 2008 Jun;87(3):367-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients.
  • BACKGROUND AND PURPOSE: To retrospectively analyse a large consecutive cohort of patients with anal cancer for treatment-related factors influencing local control and survival.
  • MATERIALS AND METHODS: All patients referred for primary radiotherapy at Medical University of Vienna in 1990-2002 with anal canal carcinoma without distant metastases were analysed.
  • RESULTS: Median age was 67 years (n=129), the UICC stage distribution was 15%, 58%, and 27% for stages I, II, and III, respectively.
  • Stage and age were significant factors for overall and colostomy-free-survival, N-stage for disease-free-survival.
  • Shorter overall treatment time favoured local control in stage T1-2 (p=.015), higher total radiation dose and female gender were associated with improved local control in T3-4 tumours (p=.021).
  • CONCLUSIONS: These results support potential improvement of anal cancer treatment by studying advanced technology such as IMRT, making it possible to tailor high-dose regions.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501453.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


49. Fujita S, Yamamoto S, Akasu T, Moriya Y: Outcome of patients with clinical stage II or III rectal cancer treated without adjuvant radiotherapy. Int J Colorectal Dis; 2008 Nov;23(11):1073-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with clinical stage II or III rectal cancer treated without adjuvant radiotherapy.
  • BACKGROUND: To clarify the indications for preoperative adjuvant radiotherapy for rectal cancer, the outcome of patients who underwent curative surgery without adjuvant radiotherapy was investigated.
  • METHODS: A total of 817 consecutive patients who underwent curative surgery for clinical stage II or III rectal cancer without preoperative adjuvant radiotherapy between 1988 and 2002 were reviewed.
  • Univariate analysis showed that sex, pathological T classification (pT), clinical N classification (cN), pathological N classification (pN), tumor site, distance from the anal verge, type of surgery, pathological stage, a positive radical margin, lymphatic invasion, and venous invasion were significantly correlated with local recurrence.
  • Multivariate analysis of preoperative factors identified cN, distance from the anal verge, and sex as statistically significant risk factors for local recurrence.
  • In patients with rectal cancer located less than 5 cm from the anal verge and with positive cN, the local recurrence rate was more than 10%.
  • CONCLUSIONS: Patients with rectal cancer located less than 5 cm from the anal verge and with clinically positive lymph nodes should be given preoperative adjuvant radiotherapy.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Colorectal Dis. 2006 Jan;8(1):34-6 [16519635.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]
  • [Cites] Dis Colon Rectum. 2006 Mar;49(3):345-52 [16532369.001]
  • [Cites] Dis Colon Rectum. 2007 Feb;50(2):156-67 [17180256.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6 Suppl 11):S64-9 [17178291.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1847-58 [15774778.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):218-26 [15711860.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1114-23 [16971718.001]
  • [Cites] Br J Surg. 1982 Oct;69(10):613-6 [6751457.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1266-74 [16915510.001]
  • [Cites] Br J Surg. 2007 Oct;94(10):1278-84 [17579345.001]
  • [Cites] Ann Surg. 2005 Oct;242(4):502-10; discussion 510-1 [16192810.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):411-23 [15875292.001]
  • [Cites] Br J Surg. 2006 Dec;93(12):1519-25 [17054311.001]
  • [Cites] Radiology. 2003 May;227(2):371-7 [12732695.001]
  • [Cites] Br J Surg. 2003 Dec;90(12):1580-5 [14648739.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6 Suppl 11):S70-4 [17178292.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8697-705 [16314629.001]
  • [Cites] Dis Colon Rectum. 2006 May;49(5):557-67 [16550319.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1215-23 [16983741.001]
  • [Cites] Br J Surg. 2006 Jul;93(7):860-5 [16710878.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):449-57 [11923599.001]
  • [Cites] Eur J Surg Oncol. 2006 Jun;32(5):520-6 [16600560.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6199-206 [16135487.001]
  • [Cites] Lancet. 1994 Sep 10;344(8924):707-11 [7915774.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):83-90 [17592295.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • (PMID = 18594841.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


50. Hosein PJ, Rocha-Lima CM: Role of combined-modality therapy in the management of locally advanced rectal cancer. Clin Colorectal Cancer; 2008 Nov;7(6):369-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of combined-modality therapy in the management of locally advanced rectal cancer.
  • The majority of patients with nonmetastatic rectal cancer are candidates for an aggressive multimodality approach with curative intent.
  • Multidisciplinary preoperative patient evaluation, better staging techniques, neoadjuvant chemoradiation, acceptance of shorter distal rectal margins, and transanal excision of T1 N0 rectal tumors in close proximity to the anal sphincter have resulted in decreased rates of abdominoperineal resections.
  • Preoperative and postoperative radiation therapy was shown to decrease the local recurrence rate, but not overall survival, in patients with resectable rectal cancer.
  • For patients with stage II or III disease, neoadjuvant continuous-infusion 5-fluorouracil (5-FU), concurrently with pelvic radiation, followed by postoperative 5-FU-based chemotherapy, remains the standard multimodality approach.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036689.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


51. Slejkovec Z, Falnoga I, Goessler W, van Elteren JT, Raml R, Podgornik H, Cernelc P: Analytical artefacts in the speciation of arsenic in clinical samples. Anal Chim Acta; 2008 Jan 21;607(1):83-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urine and blood samples of cancer patients, treated with high doses of arsenic trioxide were analysed for arsenic species using HPLC-HGAFS and, in some cases, HPLC-ICPMS.
  • The main arsenic species found in urine were As(III), MA and DMA and in blood As(V), MA and DMA.
  • The latter losses may be attributed to precipitation of As(III)-containing proteins/peptides during the methanol/water extraction procedure whereas the former losses were due to loss of specific As(III)-complexing proteins/peptides (e.g. cysteine, metallothionein, reduced GSH, ferritin) on the column (Hamilton PRP-X100) during the separation procedure.
  • Contemporary analytical protocols are not able to completely avoid artefacts due to losses from the sampling to the detection stage so that it is recommended to be careful with the explanation of results, particularly regarding metabolic and pharmacokinetic interpretations, and always aim to compare the sum of species with the total arsenic concentration determined independently.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18155413.001).
  • [ISSN] 1873-4324
  • [Journal-full-title] Analytica chimica acta
  • [ISO-abbreviation] Anal. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


52. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, De Bernardi B, Noguera R, Piqueras M, Cañete A, Castel V, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Michon J, Combaret V, Fischer M, Oberthuer A, Ambros PF, Beiske K, Bénard J, Marques B, Rubie H, Kohler J, Pötschger U, Ladenstein R, Hogarty MD, McGrady P, London WB, Laureys G, Speleman F, Vandesompele J: Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol; 2009 Jul;10(7):663-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These results were confirmed in the validation study, in which the signature was also independently statistically significant in a model adjusted for MYCN status, age, International Neuroblastoma Staging System stage, ploidy, International Neuroblastoma Pathology Classification grade of differentiation, and mitosis karyorrhexis index (odds ratios between 4.81 and 10.53 depending on the model for overall survival and 3.68 [95% CI 2.01-6.71] for progression-free survival).
  • FUNDING: The Belgian Foundation Against Cancer, the Children Cancer Fund Ghent, the Belgian Society of Paediatric Haematology and Oncology, the Belgian Kid's Fund and the Fondation Nuovo-Soldati (JV), the Fund for Scientific Research Flanders (KDP, JH), the Fund for Scientific Research Flanders, the Institute for the Promotion of Innovation by Science and Technology in Flanders, Strategisch basisonderzoek, the Fondation Fournier Majoie pour l'Innovation, the Instituto Carlos III, the Italian Neuroblastoma Foundation, the European Community under the FP6, and the Belgian programme of Interuniversity Poles of Attraction.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Eur J Cancer. 2013 Nov;49(17):3671-9 [23907002.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Cancer Cell. 2002 Nov;2(5):377-86 [12450793.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1599-609 [15090470.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):671-9 [15721472.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):337-50 [15837623.001]
  • [Cites] Oncogene. 2005 Nov 24;24(53):7902-12 [16103881.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):131-8 [16397034.001]
  • [Cites] Mol Aspects Med. 2006 Apr-Jun;27(2-3):126-39 [16469371.001]
  • [Cites] Anal Biochem. 2006 Apr 15;351(2):308-10 [16524557.001]
  • [Cites] Cancer Cell. 2006 May;9(5):333-9 [16697954.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6050-62 [16778177.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Jul;28(7):412-7 [16825985.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5070-8 [17075126.001]
  • [Cites] Genome Biol. 2006;7(9):R84 [16989664.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):217-26 [17229949.001]
  • [Cites] Lancet. 2007 Jun 23;369(9579):2106-20 [17586306.001]
  • [Cites] BMC Genomics. 2008;9:177 [18416850.001]
  • [Cites] Oncogene. 2008 May 22;27(23):3329-38 [18084322.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):3-10 [18325755.001]
  • [Cites] BMC Cancer. 2008;8:173 [18559103.001]
  • [Cites] J Natl Cancer Inst. 2008 Jul 2;100(13):940-9 [18577749.001]
  • [Cites] Cancer. 2008 Sep 15;113(6):1412-22 [18671248.001]
  • [Cites] Br J Cancer. 2008 Oct 7;99(7):1027-33 [18766186.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9735-45 [19047152.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D942-5 [18948285.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1034-40 [19171711.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1014-9 [19171715.001]
  • [CommentIn] Lancet Oncol. 2009 Jul;10(7):641-2 [19573794.001]
  • (PMID = 19515614.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA114766-05; United States / NCI NIH HHS / CA / CA114766-05; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U24 CA114766; United States / NCI NIH HHS / CA / U10 CA098543-08; None / None / / U10 CA098543-08; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098413-08; None / None / / U10 CA098413-08
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS264157; NLM/ PMC3045079
  •  go-up   go-down


53. Myerson RJ, Outlaw ED, Chang A, Birnbaum EH, Fleshman JW, Grigsby PW, Kodner IJ, Malayapa RS, Mutch MG, Parikh P, Picus J, Tan BR: Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):428-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
  • PURPOSE: To evaluate the factors associated with disease control and morbidity after radiotherapy for anal carcinoma.
  • METHODS AND MATERIALS: Between 1975 and 2005, 194 patients with localized epidermoid anal carcinoma underwent radiotherapy.
  • Univariate analysis for UNED survival showed a strong association with the T and N stage (5-year UNED rate, 88.5% +/- 3.4% for those with Stage T1-T2N0; 70.1% +/- 4.2% for Stage T3N0; and 52.7% +/- 6.6% for Stage III; p > .001) and mobility on palpation (5-year UNED rate, 89.2% +/- 4.6% for those with mobile tumors vs. 59.3% +/- 6.1% for those with tethered/fixed tumor; p > .001).
  • Of the 194 patients, 56 had 68 additional malignancies, mainly either antedating the anal cancer or outside the radiation fields.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy


54. Chamlou R, Parc Y, Simon T, Bennis M, Dehni N, Parc R, Tiret E: Long-term results of intersphincteric resection for low rectal cancer. Ann Surg; 2007 Dec;246(6):916-21; discussion 921-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of intersphincteric resection for low rectal cancer.
  • INTRODUCTION: In the treatment of very low rectal cancer, a distal resection margin of more than 1 cm can be obtained by partial internal sphincteric resection, allowing a sphincter preserving surgery.
  • Thus, intersphincteric resection (ISR) has been proposed as an alternative to abdominoperineal resection for selected low rectal cancer.
  • Cancer-related survival and locoregional recurrence rates were calculated using the Kaplan-Meier method.
  • RESULTS: Ninety patients (59 males, 31 females) with a tumor at a median distance of 35 mm (range, 22-52) from the anal verge had an ISR.
  • Thirteen patients (14.4%) died of cancer recurrence.
  • In univariate analysis, overall survival was significantly influenced by pTNM stage and T stage (pT 1-2 vs. 3-4: P = 0.008 and stage I-II vs. III-IV: P = 0.03).
  • After adjustment for age, gender, tumor level, and pTNM stage, preoperative radiotherapy was the only factor associated with a risk of fecal incontinence [OR (IC 95%) = 3.1 (1.0-9.0), P = 0.04].
  • [MeSH-major] Adenocarcinoma / epidemiology. Anal Canal / surgery. Colectomy / methods. Rectal Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043092.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Thall PF: A review of phase 2-3 clinical trial designs. Lifetime Data Anal; 2008 Mar;14(1):37-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is followed by descriptions of some particular phase 2-3 designs that have been proposed, including two-stage designs to evaluate one experimental treatment, a design that accommodates both frontline and salvage therapy in oncology, two-stage select-and-test designs that evaluate several experimental treatments, dose-ranging designs, and a seamless phase 2-3 design based on both early response-toxicity outcomes and later event times.
  • [MeSH-major] Clinical Trials, Phase II as Topic / methods. Clinical Trials, Phase III as Topic / methods. Research Design

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7199-206 [16192604.001]
  • [Cites] Stat Med. 1995 Feb 28;14(4):357-79 [7746977.001]
  • [Cites] Stat Med. 2005 May 30;24(10):1455-81 [15586395.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Stat Med. 1986 Sep-Oct;5(5):459-64 [3787000.001]
  • [Cites] Stat Med. 2007 Nov 20;26(26):4687-702 [17427204.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Stat Med. 2000 Apr 30;19(8):1011-28 [10790677.001]
  • [Cites] Cancer Treat Rep. 1985 Dec;69(12):1375-81 [4075313.001]
  • [Cites] Clin Trials. 2004 Feb;1(1):9-20 [16281458.001]
  • [Cites] Biometrics. 1989 Jun;45(2):537-47 [2765637.001]
  • [Cites] Stat Med. 1994 Mar 15-Apr 15;13(5-7):417-29 [8023026.001]
  • [Cites] Control Clin Trials. 1988 Jun;9(2):107-18 [3396362.001]
  • [Cites] Blood. 2003 Jul 15;102(2):442-8 [12560224.001]
  • [Cites] Biometrics. 2002 Dec;58(4):823-31 [12495136.001]
  • [Cites] Biometrics. 1995 Dec;51(4):1372-83 [8589229.001]
  • [Cites] Biometrics. 1987 Dec;43(4):865-74 [3427171.001]
  • [Cites] Biometrics. 2004 Sep;60(3):684-93 [15339291.001]
  • [Cites] Biometrics. 1994 Jun;50(2):337-49 [7980801.001]
  • [Cites] Clin Trials. 2007;4(2):113-24 [17456511.001]
  • [Cites] Cancer Treat Rep. 1985 Oct;69(10):1147-54 [4042093.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 18;84(6):407-14 [1531682.001]
  • [Cites] J Chronic Dis. 1961 Apr;13:346-53 [13704181.001]
  • [Cites] Stat Med. 1990 Mar;9(3):215-28 [2188324.001]
  • [Cites] Stat Med. 1988 May;7(5):571-9 [3387716.001]
  • (PMID = 17763973.001).
  • [ISSN] 1380-7870
  • [Journal-full-title] Lifetime data analysis
  • [ISO-abbreviation] Lifetime Data Anal
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 83932
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


56. Pasetto LM, Basso U, Sinigaglia G, Pucciarelli S, Friso ML, Rugge M, Toppan P, Agostini M, Monfardini S: Rectal cancer adjuvant chemotherapy: when is more useful? Anticancer Res; 2008 May-Jun;28(3B):1805-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal cancer adjuvant chemotherapy: when is more useful?
  • THE AIM of the study was to evaluate time-to-progression (TTP) of rectal cancer in a group of patients receiving adjuvant chemotherapy (CHT) after combined neoadjuvant treatment.
  • PATIENTS AND METHODS: From January 2000 to December 2005, 101 consecutive rectal cancer patients who had been neoadjuvantly treated and had underne adjuvant CHT were retrospectively examined.
  • Forty-two patients had a lower (< or =5 cm from the anal verge), 54 a middle (from 6 to 10 cm) and 5 a higher (=10 cm) rectal lesion.
  • CONCLUSION: In our series, neither administration of oxaliplatin-based adjuvant chemotherapy (p=0.44) nor age > or =70 years (p=0.51), clinical stage III (p=0.67), tumour down-staging (p=0.44) and achievement of pCR (p=0.66) appeared to have a significant impact on TTP; only pN+ (patients "not responders" to a neoadjuvant CHT-RT) influenced local relapse requiring more accurate postoperative treatment and confirming the literature data about the utility of adjuvant therapy in stage III disease.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630464.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


57. Oue T, Fukuzawa M, Okita H, Mugishima H, Horie H, Hata J, Saito M, Nozaki M, Chin M, Nakadate H, Hinotsu S, Koshinaga T, Kaneko Y, Kitano Y, Tanaka Y, Japan Wilms Tumor Study (JWiTS) Group: Outcome of pediatric renal tumor treated using the Japan Wilms Tumor Study-1 (JWiTS-1) protocol: a report from the JWiTS group. Pediatr Surg Int; 2009 Nov;25(11):923-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical stage was classified according to the Japanese Staging System.
  • In the nephroblastoma patients, 5-year OS was 90.5% for stage I disease, 92.2% for stage II, 90.9% for stage III, 86.7% for stage IV, and 78.7% for stage V.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1981 Jul;12(7):646-57 [7275104.001]
  • [Cites] Med Pediatr Oncol. 1994;22(4):221-7 [8107651.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2554-62 [16904312.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):311-9 [11332141.001]
  • [Cites] Lancet. 2004 Oct 2-8;364(9441):1229-35 [15464183.001]
  • [Cites] Am J Surg Pathol. 1989 Jun;13(6):439-58 [2543225.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3719-24 [11533093.001]
  • [Cites] Lifetime Data Anal. 2007 Dec;13(4):463-70 [18027087.001]
  • [Cites] J Urol. 1991 Aug;146(2 ( Pt 2)):514-8 [1650403.001]
  • [Cites] J Urol. 1987 Oct;138(4 Pt 2):968-73 [2821293.001]
  • [Cites] Cancer. 1984 Dec 15;54(12):2978-87 [6093989.001]
  • [Cites] Cancer. 1978 May;41(5):1937-48 [206343.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):292-7 [10024113.001]
  • [Cites] Curr Probl Cancer. 2005 Sep-Oct;29(5):221-60 [16216623.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Aug;47(8):712-27 [18464243.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9138-45 [16172460.001]
  • [Cites] J Pediatr Surg. 1977 Oct;12(5):631-8 [72143.001]
  • [Cites] Cancer. 1976 Aug;38(2):633-46 [184912.001]
  • [Cites] Mol Carcinog. 2008 Sep;47(9):660-6 [18286482.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7312-21 [16129848.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2132-7 [7931484.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jun;45(6):592-601 [16518847.001]
  • (PMID = 19701757.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


58. Liang JT, Lai HS, Lee PH: Multimedia article. Laparoscopic abdominoperineal resection for lower rectal cancers: how do we do it? Surg Endosc; 2006 Apr;20(4):695-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The appropriateness of the laparoscopic approach for the resection of rectal cancer has been controversial, although it is well established in colon cancer.
  • METHODS: Patients with lower rectal adenocarcinoma located within 6 cm above the anal verge were recruited and subjected to laparoscopic APR.
  • Physical status (American Society of Anesthesiology classification) was class I in 12, class II in eight, and class III in two patients.
  • Two patients were in pathologic TNM stage I, 14 in stage II, and six in stage III.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1481-5 [12432295.001]
  • [Cites] World J Surg. 2002 Mar;26(3):377-83 [11865378.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):46-54; discussion 54-5 [9660024.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2000 Feb;10(1):47-53 [10706303.001]
  • [Cites] World J Surg. 2003 Feb;27(2):190-6 [12616435.001]
  • [Cites] Ann Surg. 1967 Sep;166(3):420-7 [6039601.001]
  • (PMID = 16502195.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Video-Audio Media
  • [Publication-country] Germany
  •  go-up   go-down


59. Yamada K, Ogata S, Saiki Y, Fukunaga M, Tsuji Y, Takano M: Long-term results of intersphincteric resection for low rectal cancer. Dis Colon Rectum; 2009 Jun;52(6):1065-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of intersphincteric resection for low rectal cancer.
  • PURPOSE: Intersphincteric resection has been performed as an alternative to abdominoperineal resection for low rectal cancer.
  • METHODS: Between 1994 and 2006, 107 consecutive patients with low rectal cancer had curative intersphincteric resection, categorized as total, subtotal, or partial resection of the internal anal sphincter.
  • The five-year disease-free survival rates classified according to the TNM stage were 100 percent for stage I, 83.5 percent for stage II, and 72.0 percent for stage III cases.
  • CONCLUSION: Provided strict selection criteria are used, intersphincteric resection may be the optimal sphincter-preserving surgery for low rectal cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581848.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Matsopoulos GK, Mouravliansky NA, Asvestas PA, Delibasis KK, Kouloulias V: Thoracic non-rigid registration combining self-organizing maps and radial basis functions. Med Image Anal; 2005 Jun;9(3):237-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An automatic three-dimensional non-rigid registration scheme is proposed in this paper and applied to thoracic computed tomography (CT) data of patients with stage III non-small cell lung cancer (NSCLC).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiography. Imaging, Three-Dimensional / methods. Lung Neoplasms / radiography. Pattern Recognition, Automated / methods. Radiographic Image Interpretation, Computer-Assisted / methods. Radiography, Thoracic / methods. Subtraction Technique

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854844.001).
  • [ISSN] 1361-8415
  • [Journal-full-title] Medical image analysis
  • [ISO-abbreviation] Med Image Anal
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. El Badry AA, El-Fadle AA, El-Balshy AL: Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma. MedGenMed; 2007;9(3):3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma.
  • The present study was designed to clarify the role of TIMP-2 in nasopharyngeal carcinoma (NPC) patients and to evaluate its importance relative to clinicopathologic parameters.
  • Clinically, in accordance with TNM classification (T: tumor size, N: lymph node involvement, M: distant metastasis), 8 cases were diagnosed as stage II, 12 as stage III, and 10 cases as stage IV; however, pathologic typing with use of the World Health Organization (WHO) classification revealed the presence of 9 specimens of squamous cell carcinoma (WHO type 1), 6 cases of nonkeratinizing carcinoma (WHO type 2), and 15 cases of undifferentiated carcinoma (WHO type 3).
  • In addition, there was a significant positive correlation between TIMP-2 protein positivity and either the clinical staging or the histopathologic typing (P < .01) using Chi-square test (x(2)), suggesting that TIMP-2 can be used as a marker of the severity of NPC.Accordingly, we can assume that TIMP-2 may play a role in regional lymph node and/or distant metastasis and in progression of squamous cell carcinoma.
  • [MeSH-major] Carcinoma / chemistry. Carcinoma / enzymology. Nasopharyngeal Neoplasms / chemistry. Nasopharyngeal Neoplasms / enzymology. Tissue Inhibitor of Metalloproteinase-2 / analysis

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Nov;189(3):300-8 [10547590.001]
  • [Cites] Am J Clin Pathol. 1993 Jan;99(1):18-23 [8422010.001]
  • [Cites] Adv Exp Med Biol. 2000;465:469-83 [10810650.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):215-8 [10901373.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):895-904 [10987249.001]
  • [Cites] Int J Oncol. 2000 Dec;17(6):1099-105 [11078794.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):44-50 [11241310.001]
  • [Cites] J Med Invest. 2001 Feb;48(1-2):31-43 [11286015.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):813-20 [11448356.001]
  • [Cites] Int J Colorectal Dis. 2001 Jun;16(3):133-40 [11459286.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3113-9 [11595703.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):26-34 [11796838.001]
  • [Cites] Isr Med Assoc J. 2002 Apr;4(4):247-51 [12001695.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7414-9 [12032297.001]
  • [Cites] Ai Zheng. 2002 Jan;21(1):91-4 [12500407.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Otolaryngol Head Neck Surg. 1983 Jun;91(3):255-62 [6308537.001]
  • [Cites] J Biol Chem. 1989 Oct 15;264(29):17374-8 [2793861.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):339-44 [7927938.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Cancer Res. 1996 Apr 1;56(7):1654-9 [8603416.001]
  • [Cites] FEBS Lett. 1996 May 6;385(3):238-40 [8647259.001]
  • [Cites] Cancer Res. 1996 Jun 15;56(12):2707-10 [8665498.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):139-44 [8988738.001]
  • [Cites] Eur J Cell Biol. 1997 Oct;74(2):111-22 [9352216.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):439-44 [9398846.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):650-5 [9484825.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1359-66 [9529029.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1623-8 [9815852.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):467-73 [9927064.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1589-92 [10365151.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21491-4 [10419448.001]
  • [Cites] Head Neck. 1999 Oct;21(7):627-38 [10487950.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16485-90 [1653238.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1085-91 [10810401.001]
  • (PMID = 18092010.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2
  • [Other-IDs] NLM/ PMC2100075
  •  go-up   go-down


62. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK: Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum; 2008 Feb;51(2):147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
  • PURPOSE: The incidence of anal canal squamous-cell carcinoma is increasing.
  • METHODS: Using one database, we identified 131 Stages I-III patients treated for primary anal canal squamous-cell carcinoma at our institution from December 1986 to August 2006, with minimum six-month follow-up.
  • RESULTS: Of 131 patients (median age, 58.3 years; median follow-up, 2.9 (range, 0.6-11.2) years), 66 percent were females, 43.5 percent were Stage II, and 11 (8 percent) were HIV-positive.
  • Almost all patients undergoing radiotherapy (96.7 percent, 118/122) also had chemotherapy: 118 (100 percent, Stages I-III) had concurrent chemotherapy: (98 (83.8 percent) mitomycin/5-fluorouracil, 12 (10.2 percent) cisplatin/5-fluorouracil, 8 (6.8 percent) 5-fluorouracil alone); 35 of 46 (76 percent) Stage III patients received induction chemotherapy (34 (97.1 percent) cisplatin/5-fluorouracil, 1 (2.8 percent) 5-fluorouracil alone).
  • Many (44 percent Stages I/II, 48.9 percent Stage III) required dose adjustments.
  • Bivariate analyses demonstrated that T stage (P=0.0019), completion of radiotherapy, and total radiotherapy dose (P=0.03) were all significantly associated with treatment failure.
  • On multivariate analyses, disease stage (P=0.05) and completion of radiotherapy (P=0.01) remained significant predictors of relapse-free survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Colon Rectum. 2008 May;51(5):620
  • (PMID = 18180997.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Rivera R, Barboglio PG, Hellinger M, Gousse AE: Staging rectourinary fistulas to guide surgical treatment. J Urol; 2007 Feb;177(2):586-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Etiology was rectal injury during open radical prostatectomy in 5 patients, laparoscopic prostatectomy in 1, radiation induced fistula for prostate cancer treatment (brachytherapy and external beam radiation therapy) in 2, neoadjuvant external beam radiation therapy in 2, ischial decubitus ulcer in 3 with spinal cord injury, and cryotherapy and external beam radiation therapy in 1.
  • Cases were staged as stage I--low (less than 4 cm from anal verge and nonirradiated), stage II--high (more than 4 cm from anal verge and nonirradiated), stage III--small (less than 2 cm irradiated fistula), stage IV--large (more than 2 cm irradiated fistula) and stage V--large (ischial decubitus fistula).
  • Diverting colostomy was performed for stages III to V 6 weeks before definitive therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222638.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, Aoyagi Y: Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci; 2010 Dec;55(12):3576-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma.
  • BACKGROUND: Alpha-fetoprotein (AFP) has been widely used as a diagnostic master for hepatocellular carcinoma (HCC), and the fucosylated fraction of AFP (AFP-L3) has been reported to be a specific marker for HCC.
  • The positivity rates for μ-TAS AFP-L3 were higher at each tumor stage than those of LiBASys AFP-L3 (μ-TAS/LiBASys: stage I, 44.2%/16.3%; stage II, 52.9%/37.5%; stage III, 66.4%/44.5%; stage IV, 82.8%/65.5%).
  • CONCLUSIONS: μ-TAS AFP-L3 is more sensitive for discriminating HCC than the conventional LiBASys AFP-L3, particularly in subgroups with lower AFP concentrations and early-stage HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Immunoassay / methods. Liver Neoplasms / diagnosis. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Electrophoresis. 2008 Apr;29(7):1399-406 [18384019.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Dec;16(12):1378-83 [11851836.001]
  • [Cites] Am J Gastroenterol. 1999 Oct;94(10):3028-33 [10520864.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2076-82 [9827711.001]
  • [Cites] Hepatology. 1993 Jan;17(1):50-2 [7678576.001]
  • [Cites] J Gastroenterol. 2003;38(3):207-15 [12673442.001]
  • [Cites] Anal Biochem. 2009 May 15;388(2):306-11 [19250915.001]
  • [Cites] Cancer Res. 1968 Jul;28(7):1344-50 [4174340.001]
  • [Cites] Am J Gastroenterol. 1998 Dec;93(12):2452-6 [9860408.001]
  • [Cites] J Gastroenterol. 2007 Dec;42(12):962-8 [18085353.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5419-23 [7693340.001]
  • [Cites] J Hepatol. 1999 Jan;30(1):125-30 [9927159.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):769-74 [2448024.001]
  • [Cites] Cancer. 1970 May;25(5):1091-8 [5443731.001]
  • [Cites] J Clin Gastroenterol. 2001 Mar;32(3):240-4 [11246354.001]
  • [Cites] Hepatology. 2006 Dec;44(6):1518-27 [17133456.001]
  • [Cites] Hepatol Res. 2007 Nov;37(11):914-22 [17610501.001]
  • [Cites] Am J Clin Pathol. 1999 Jun;111(6):811-6 [10361518.001]
  • [Cites] Anal Chem. 1998 Mar 1;70(5):954-7 [9511471.001]
  • (PMID = 20407827.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Plant Lectins; 0 / alpha-Fetoproteins
  •  go-up   go-down


65. Lupattelli M, Mascioni F, Bellavita R, Draghini L, Tarducci R, Castagnoli P, Russo G, Aristei C: Long-term anorectal function after postoperative chemoradiotherapy in high-risk rectal cancer patients. Tumori; 2010 Jan-Feb;96(1):34-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term anorectal function after postoperative chemoradiotherapy in high-risk rectal cancer patients.
  • AIMS AND BACKGROUND: After sphincter-preserving surgery for rectal cancer and postoperative radiochemotherapy, many patients have unsatisfactory anorectal functional results which are not considered by the most common toxicity scales.
  • The aim of the present study was to retrospectively assess the long-term incidence of impaired anorectal function in rectal cancer patients who underwent anterior resection and postoperative radiochemotherapy.
  • METHODS: Ninety-nine patients who underwent sphincter-saving surgery and postoperative radiochemotherapy for stage II-III rectal cancer from July 1991 to January 2002 were given a questionnaire on anorectal function.
  • [MeSH-major] Anal Canal / physiopathology. Rectal Neoplasms / therapy. Rectum / physiopathology

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20437855.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Elgaili EM, Abuidris DO, Rahman M, Michalek AM, Mohammed SI: Breast cancer burden in central Sudan. Int J Womens Health; 2010;2:77-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer burden in central Sudan.
  • Breast cancer is a worldwide disease resulting in many deaths.
  • Although breast cancer incidence is lower in Sub-Saharan African countries than in developed countries, African women are more likely than women in the developed world to be diagnosed at later stages of the disease and, thus, are more likely to die from it.
  • This descriptive study was undertaken to shed light on the type, stage and age distribution of breast cancer at diagnosis in women living in central Sudan encompassing al-Gezira, Blue Nile, White Nile, and Sennar States.
  • Cases comprised 1255 women from central Sudan diagnosed with breast cancer and referred to and treated at Institute of Nuclear Medicine, Molecular Biology, and Oncology, from January 1999 to December 2006.
  • Invasive ductal carcinoma was the most common pathology (82%) and women presenting with stage III or higher tumors that had already metastasized, while ductal carcinoma in situ was the least prevalent (0.5%) finding.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21072300.001).
  • [ISSN] 1179-1411
  • [Journal-full-title] International journal of women's health
  • [ISO-abbreviation] Int J Womens Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2971742
  • [Keywords] NOTNLM ; Africa / epidemiology / estrogen receptor / female breast cancer / progesterone receptor
  •  go-up   go-down


67. Fukunaga Y, Higashino M, Tanimura S, Takemura M, Fujiwara Y: Laparoscopic rectal surgery for middle and lower rectal cancer. Surg Endosc; 2010 Jan;24(1):145-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic rectal surgery for middle and lower rectal cancer.
  • BACKGROUND: The usefulness of laparoscopic low anterior resection for middle and lower rectal cancer remains controversial.
  • METHODS: Retrospective assessment was performed on 98 patients (51 with middle and 47 with lower rectal cancer) who underwent laparoscopic rectal surgery since 1998.
  • Cancers were classified as middle or lower rectal based on distance from the distal tumor border to the anal verge (<8 cm or >or=8 cm).
  • The 5-year disease-free/overall survival rates were 82.3/95.7% in stage I, 55.1/72.0% in stage II, and 59.5/80.7% in stage III.
  • It is a useful option even for advanced lower rectal cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2010 Dec;24(12):3241-3 [20372934.001]
  • [Cites] Br J Surg. 1994 May;81(5):648-52 [8044537.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Surg Laparosc Endosc. 1991 Sep;1(3):144-50 [1688289.001]
  • [Cites] Dis Colon Rectum. 1993 Sep;36(9):858-61 [8397078.001]
  • [Cites] Hepatogastroenterology. 2007 Jan-Feb;54(73):85-90 [17419237.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):599-601 [4027529.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1124-32 [15997446.001]
  • [Cites] Ann Surg. 2001 Aug;234(2):190-7 [11505064.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):844-51 [18330644.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):214-6 [8689166.001]
  • [Cites] J Am Coll Surg. 2001 Nov;193(5):579-84 [11708519.001]
  • [Cites] World J Surg. 2008 Sep;32(9):2095-100 [18612681.001]
  • [Cites] Br J Surg. 2003 Jul;90(7):867-71 [12854115.001]
  • [Cites] Surgery. 1994 Nov;116(5):842-6 [7940187.001]
  • [Cites] Br J Surg. 1999 Dec;86(12):1532-7 [10594501.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):335-42 [12616116.001]
  • [Cites] Surg Endosc. 1996 Aug;10(8):809-12 [8694943.001]
  • [Cites] Acta Chir Belg. 1994 Sep-Oct;94(5):258-62 [7976066.001]
  • [Cites] Ann Surg. 2008 Apr;247(4):627-32 [18362625.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):315-21 [11289275.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):281-9 [14691716.001]
  • [Cites] Am J Surg. 1982 Sep;144(3):350-4 [7114377.001]
  • [Cites] Br J Surg. 1998 Apr;85(4):526-9 [9607540.001]
  • (PMID = 19517172.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


68. O'Neil BH, Tepper JE: Current options for the management of rectal cancer. Curr Treat Options Oncol; 2007 Oct;8(5):331-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current options for the management of rectal cancer.
  • Patients diagnosed with rectal cancer should undergo locoregional staging with transrectal endoscopic ultrasound (EUS) or surface coil array MRI of the pelvis if that technique is available.
  • Patients thought to have more than very early stage (T1 or T2) disease should undergo abdominal imaging as well by CT or MRI, and chest imaging with either CXR or preferably CT.
  • The care of rectal cancer patients should be coordinated amongst an experienced multidisciplinary team to maximize the chance of cure and to minimize both local recurrence and complications of therapy.
  • For patients with very early stage disease (T1N0 or T2N0), local resection with or without chemoradiation may be adequate therapy, but these patients must be selected carefully and should be without any poor prognostic factors.
  • For the majority of patients with T3N0 or greater rectal cancer, standard therapy consists of neoadjuvant continuous 5-FU and radiation followed by surgery and further chemotherapy (either with 5-FU, capecitabine, or FOLFOX).
  • The use of capecitabine, irinotecan, and oxaliplatin during radiotherapy shows promise, but remains investigational pending results of phase III studies.
  • Select patients with high (>10 cm from the anal verge) uT3N0 tumors may be at sufficiently low risk of local recurrence to justify omission of radiotherapy.
  • Patients with stage IV rectal cancer may still require local therapy with radiation, surgery, or both; however, care should be taken in these patients that chemotherapy is not excessively delayed as this is the one modality in this case that can result in improved survival.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Sep;12(9):1559-63 [3759580.001]
  • [Cites] Ann Surg. 2002 Nov;236(5):583-92 [12409664.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14 ):980-7 [9091798.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):738-44 [17208931.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1114-23 [16971718.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):335-41 [1728364.001]
  • [Cites] Eur J Surg Oncol. 1986 Dec;12(4):373-7 [3780991.001]
  • [Cites] Eur J Cancer. 1994;30A(8):1092-5 [7654436.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3623-8 [14512393.001]
  • [Cites] Br J Surg. 2007 Feb;94(2):129-31 [17256808.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1155-60 [16035135.001]
  • [Cites] Oncology (Williston Park). 1989 May;3(5):137-42; discussion 142, 146-8 [2577881.001]
  • [Cites] Clin Radiol. 2006 Nov;61(11):916-23 [17018303.001]
  • [Cites] Oncology (Williston Park). 2006 Apr;20(5):461-9; discussion 469-70, 473-5 [16739745.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9243-9 [16230673.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1421-9 [2920368.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):386-96 [12243812.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):912-7 [17325705.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):166-74 [14701779.001]
  • [Cites] Br J Cancer. 1984 Oct;50(4):435-42 [6487514.001]
  • [Cites] Ann Oncol. 2007 Jul;18 Suppl 9:ix122-6 [17631564.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Br J Cancer. 2006 Sep 18;95(6):710-6 [16940980.001]
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] Semin Radiat Oncol. 2003 Oct;13(4):389-402 [14586829.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8697-705 [16314629.001]
  • [Cites] Arch Surg. 1991 Jun;126(6):696-701; discussion 701-2 [2039356.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2557-62 [16636336.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):549-57 [1548520.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):650-5 [16446336.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):762-71 [17011451.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):246-51 [16282246.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Nov 15;27(4):779-83 [8244805.001]
  • [Cites] Semin Radiat Oncol. 2003 Oct;13(4):469-77 [14586835.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1353-65 [15868235.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):668-74 [16446339.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1785-96 [15067027.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):201-5 [16814947.001]
  • [Cites] N Engl J Med. 1985 Jun 6;312(23 ):1465-72 [2859523.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Ann Surg. 2007 May;245(5):726-33 [17457165.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):110-7 [17194912.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):63-9; discussion 69-70 [1733375.001]
  • (PMID = 18181024.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 K23 CA 118431-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  • [Number-of-references] 51
  •  go-up   go-down


69. Zhang L, Chen J, Ke Y, Mansel RE, Jiang WG: Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol; 2005 Oct 13;3:68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance.
  • This study examined PlGF expression at protein and message levels in non-small cell lung cancer (NSCLC), in which no reports on the significance of PlGF expression is available to date.
  • RESULTS: PlGF was positively stained mainly in cytoplasm of lung cancer cells.
  • Real time PCR analysis revealed that PlGF mRNA was higher in the cancer tissue than normal tissue (0.95 +/- 0.19 vs. 0.57 +/- 0.24; p < 0.005) and that PlGF mRNA was significant higher in III-IV stage patients than in I-II stage patients (1.03 +/- 0.20 vs. 0.80 +/- 0.17; p = 0.011).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 1999 Jan;14(1):161-8 [9863024.001]
  • [Cites] J Biol Chem. 1994 Oct 14;269(41):25646-54 [7929268.001]
  • [Cites] J Biol Chem. 1995 Mar 31;270(13):7717-23 [7706320.001]
  • [Cites] Oncogene. 1993 Apr;8(4):925-31 [7681160.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):66-70 [7596436.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):62-6 [7596435.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(11):1628-36 [15951164.001]
  • [Cites] Tumour Biol. 2004 Jan-Apr;25(1-2):1-6 [15192305.001]
  • [Cites] J Clin Pathol. 2004 Jun;57(6):591-7 [15166262.001]
  • [Cites] Adv Cancer Res. 1995;67:281-316 [8571818.001]
  • [Cites] J Biol Chem. 1996 Feb 9;271(6):3154-62 [8621715.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2671-6 [8653715.001]
  • [Cites] Anal Biochem. 1997 Feb 15;245(2):154-60 [9056205.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 27;235(3):493-8 [9207183.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1069-77 [12454810.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):10931-4 [1375931.001]
  • [Cites] J Clin Pathol. 1998 Oct;51(10):771-5 [10023341.001]
  • [Cites] Nat Med. 2001 May;7(5):575-83 [11329059.001]
  • (PMID = 16223445.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1276823
  •  go-up   go-down


70. Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, Xu Y, Li H, Vyas S, Mu Z, Chapman PB, Krown SE, Panageas K, Terzulli SL, Old LJ, Houghton AN, Wolchok JD: Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun; 2009 Jun 05;9:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients had no evidence of disease; 10 (53%) had stage III disease, 3 each (16%) had stage IIB and IV disease, 2 (11%) had choroidal and 1 (5%) had anal mucosal involvement.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene Ther. 2003 Sep;10(20):1754-65 [12939642.001]
  • [Cites] Surgery. 2000 Aug;128(2):273-80 [10923004.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Jul;77(7):4260-4 [6933476.001]
  • [Cites] J Exp Med. 1982 Dec 1;156(6):1755-66 [7175440.001]
  • [Cites] J Invest Dermatol. 1988 Apr;90(4):459-66 [3280698.001]
  • [Cites] J Immunol. 1995 Apr 15;154(8):3961-8 [7706734.001]
  • [Cites] J Exp Med. 1995 Aug 1;182(2):459-65 [7543139.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83 [8610135.001]
  • [Cites] Science. 1996 Jul 19;273(5273):352-4 [8662521.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4749-57 [8840994.001]
  • [Cites] J Immunother. 1997 Jan;20(1):15-25 [9101410.001]
  • [Cites] Am J Pathol. 1997 Jun;150(6):2143-52 [9176405.001]
  • [Cites] J Clin Invest. 1998 Sep 15;102(6):1258-64 [9739060.001]
  • [Cites] J Immunol. 1999 May 15;162(10):5813-20 [10229815.001]
  • [Cites] Surgery. 1999 Aug;126(2):112-20 [10455872.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8114-21 [16299244.001]
  • [Cites] Cancer Immun. 2006;6:8 [16626110.001]
  • [Cites] Vaccine. 2006 May 22;24(21):4582-5 [16188351.001]
  • [Cites] Cytotherapy. 2006;8(5):498-508 [17050255.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4112-9 [17371966.001]
  • [Cites] J Exp Med. 2007 Jun 11;204(6):1405-16 [17535971.001]
  • [Cites] Mol Ther. 2007 Nov;15(11):2044-50 [17726460.001]
  • [Cites] Eur J Immunol. 2008 Feb;38(2):350-63 [18200635.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Oncologist. 2008;13 Suppl 4:2-9 [19001145.001]
  • [Cites] Oncologist. 2008;13 Suppl 4:10-5 [19001146.001]
  • [Cites] Mol Ther. 2008 Dec;16(12):2022-9 [18797450.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5 [19074257.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):967-72 [12006508.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1717-22 [10587362.001]
  • [Cites] J Immunol. 1999 Dec 15;163(12):6867-75 [10586088.001]
  • [Cites] Annu Rev Immunol. 2004;22:745-63 [15032595.001]
  • (PMID = 19496531.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA033049-24; United States / NCI NIH HHS / CA / CA033049-24; United States / NCI NIH HHS / CA / P01CA33049; United States / NCI NIH HHS / CA / P01 CA033049; United States / NCI NIH HHS / CA / R01 CA056821; United States / NCCIH NIH HHS / AT / P50AT002779
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / HLA-A2 Antigen; 0 / Membrane Glycoproteins; 0 / PMEL protein, human; 0 / Peptides; 0 / Si protein, mouse; 0 / Vaccines, DNA; 0 / gp100 Melanoma Antigen; 0 / gp100(280-288) melanoma antigen peptide
  • [Other-IDs] NLM/ NIHMS201057; NLM/ PMC2888533
  •  go-up   go-down


71. Yasumoto T, Shimizu J, Watanabe N, Inada M, Nakata S, Sato M, Hayashi S, Dono K, Kitada M, Shimano T: [A case of bile peritonitis caused by jejunal perforation after radiofrequency ablation for the multiple liver metastases from cholangiocarcinoma successfully treated with various interventional radiological procedures after pancreatoduodenectomy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2093-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lesion was judged to be T3, N1, H0, P0, M0 and Stage III, and then he received various treatments including thermotherapy, CD3-activated T lymphocyte therapy.
  • Fifty days after the ablation, T-tube, with which pancreatic fluid and bile was induced from the cecal portion of the anastomosed jejunum to the anal side slipping through the perforated point, was successfully inserted through right flank, and resulted in complete recovery from a major technical complication of the bile peritonitis.


72. Andersen JD, Boylan KL, Jemmerson R, Geller MA, Misemer B, Harrington KM, Weivoda S, Witthuhn BA, Argenta P, Vogel RI, Skubitz AP: Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients. J Ovarian Res; 2010 Sep 10;3:21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients.
  • BACKGROUND: New biomarkers that replace or are used in conjunction with the current ovarian cancer diagnostic antigen, CA125, are needed for detection of ovarian cancer in the presurgical setting, as well as for detection of disease recurrence.
  • We previously demonstrated the upregulation of leucine-rich alpha-2-glycoprotein-1 (LRG1) in the sera of ovarian cancer patients compared to healthy women using quantitative mass spectrometry.
  • METHODS: LRG1 was quantified by ELISA in serum from two relatively large cohorts of women with ovarian cancer and benign gynecological disease.
  • The expression of LRG1 in ovarian cancer tissues and cell lines was examined by gene microarray, reverse-transcriptase polymerase chain reaction (RT-PCR), Western blot, immunocytochemistry and mass spectrometry.
  • RESULTS: Mean serum LRG1 was higher in 58 ovarian cancer patients than in 56 healthy women (89.33 ± 77.90 vs. 42.99 ± 9.88 ug/ml; p = 0.0008) and was highest among stage III/IV patients.
  • In a separate set of 193 pre-surgical samples, LRG1 was higher in patients with serous or clear cell ovarian cancer (145.82 ± 65.99 ug/ml) compared to patients with benign gynecological diseases (82.53 ± 76.67 ug/ml, p < 0.0001).
  • LRG1 mRNA levels were higher in ovarian cancer tissues and cell lines compared to their normal counterparts when analyzed by gene microarray and RT-PCR.
  • LRG1 protein was detected in ovarian cancer tissue samples and cell lines by immunocytochemistry and Western blotting.
  • LRG1 protein was also detected in the conditioned media of ovarian cancer cell culture by ELISA, Western blotting, and mass spectrometry.
  • CONCLUSIONS: Serum LRG1 was significantly elevated in women with ovarian cancer compared to healthy women and women with benign gynecological disease, and was only moderately correlated with CA125.
  • Ovarian cancer cells secrete LRG1 and may contribute directly to the elevated levels of LRG1 observed in the serum of ovarian cancer patients.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20831812.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106878-05; United States / NCI NIH HHS / CA / R01 CA106878-05
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2949730
  •  go-up   go-down


73. Filippi L, Cavallaro G, Fiorini P, Daniotti M, Benedetti V, Cristofori G, Araimo G, Ramenghi L, La Torre A, Fortunato P, Pollazzi L, la Marca G, Malvagia S, Bagnoli P, Ristori C, Dal Monte M, Bilia AR, Isacchi B, Furlanetto S, Tinelli F, Cioni G, Donzelli G, Osnaghi S, Mosca F: Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr; 2010 Nov 18;10:83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS/DESIGN: Preterm newborns (gestational age at birth lower than 32 weeks) with stage 2 ROP (zone II-III without plus) will be randomized, according to their gestational age, to receive propranolol added to standard treatment (treatment adopted by the ETROP Cooperative Group) or standard treatment alone.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Retina. 2008 Mar;28(3 Suppl):S19-25 [18317339.001]
  • [Cites] Br J Ophthalmol. 2008 May;92(5):689-93 [18408080.001]
  • [Cites] Retina. 2008 Jun;28(6):831-8 [18536599.001]
  • [Cites] N Engl J Med. 2008 Jun 12;358(24):2649-51 [18550886.001]
  • [Cites] Prog Retin Eye Res. 2008 Jul;27(4):331-71 [18653375.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5177-82 [18708611.001]
  • [Cites] Growth Factors. 2008 Dec;26(6):325-30 [19021032.001]
  • [Cites] J Pharm Biomed Anal. 2008 Dec 15;48(5):1392-6 [18980824.001]
  • [Cites] Brain Behav Immun. 2009 Feb;23(2):267-75 [18996182.001]
  • [Cites] Pediatrics. 2009 Mar;123(3):e484-9 [19221153.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2009 Aug;297(2):R258-64 [19458283.001]
  • [Cites] Oncol Rep. 2009 Oct;22(4):825-30 [19724861.001]
  • [Cites] Nat Med. 1995 Oct;1(10):1024-8 [7489357.001]
  • [Cites] Arch Ophthalmol. 1996 Feb;114(2):150-4 [8573016.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1219-28 [8859081.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Growth Factors. 1998;16(1):1-9 [9777366.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):16349-54 [10347193.001]
  • [Cites] Development. 2005 Apr;132(8):1855-62 [15790963.001]
  • [Cites] Pediatrics. 2005 Jul;116(1):15-23 [15995025.001]
  • [Cites] Auton Neurosci. 2005 Aug 31;121(1-2):33-9 [15961351.001]
  • [Cites] Circ Res. 2005 Nov 25;97(11):1182-9 [16239589.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):369-75 [16428474.001]
  • [Cites] Arch Ophthalmol. 2006 Feb;124(2):199-202 [16476889.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2744-9 [16381019.001]
  • [Cites] Nat Med. 2006 Aug;12(8):939-44 [16862152.001]
  • [Cites] Br J Ophthalmol. 2006 Nov;90(11):1378-82 [16914473.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10357-64 [17079456.001]
  • [Cites] Eur J Pharmacol. 2006 Dec 28;553(1-3):54-60 [17070516.001]
  • [Cites] Epilepsia. 2009 Dec;50(12):2658-62 [19682026.001]
  • [Cites] J Pediatr. 2010 Apr;156(4):550-5 [20056237.001]
  • [Cites] Arch Ophthalmol. 2010 Jun;128(6):663-71 [20385926.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3709-13 [20181841.001]
  • [Cites] Pediatrics. 2009 Sep;124(3):e423-31 [19706583.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2011 Jan;52(1):155-70 [20739470.001]
  • [Cites] Pediatrics. 2003 Nov;112(5):1016-20 [14595040.001]
  • [Cites] Arch Ophthalmol. 2003 Dec;121(12):1684-94 [14662586.001]
  • [Cites] Physiology (Bethesda). 2004 Aug;19:176-82 [15304631.001]
  • [Cites] Pediatr Res. 2004 Nov;56(5):768-74 [15319463.001]
  • [Cites] Pediatrics. 1977 Nov;60(5):655-68 [578921.001]
  • [Cites] Am J Dis Child. 1980 Jul;134(7):707-8 [7395835.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1390-5 [10581081.001]
  • [Cites] Pediatrics. 2000 Feb;105(2):295-310 [10654946.001]
  • [Cites] J Biol Chem. 2000 May 5;275(18):13802-11 [10788502.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2866-9 [11306460.001]
  • [Cites] FASEB J. 2001 May;15(7):1215-7 [11344092.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5804-8 [11331770.001]
  • [Cites] Pharmacol Rev. 2001 Jun;53(2):319-56 [11356987.001]
  • [Cites] EMBO J. 2001 Jun 1;20(11):2768-78 [11387210.001]
  • [Cites] Arch Ophthalmol. 2001 Aug;119(8):1129-33 [11483078.001]
  • [Cites] Childs Nerv Syst. 2002 Apr;18(3-4):137-41 [11981620.001]
  • [Cites] Ophthalmology. 2002 May;109(5):928-34; discussion 935 [11986099.001]
  • [Cites] Ophthalmology. 2002 May;109(5):936-41 [11986101.001]
  • [Cites] Front Biosci. 2003 May 1;8:d1030-43 [12700061.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20681-6 [12670949.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jul;80(1):63-70 [12889599.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4514-21 [14555525.001]
  • [Cites] Am J Dis Child. 1980 Sep;134(9):819-20 [6998280.001]
  • [Cites] Pediatrics. 1984 Jan;73(1):82-96 [6419199.001]
  • [Cites] Pediatrics. 1987 May;79(5):663-9 [3575019.001]
  • [Cites] Hypertension. 1988 Mar;11(3 Pt 2):II21-9 [2895072.001]
  • [Cites] Ophthalmology. 1991 Nov;98(11):1628-40 [1800923.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Endocrinology. 1993 Aug;133(2):848-59 [7688292.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1994 Jan;35(1):101-11 [7507904.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):905-9 [7846076.001]
  • [Cites] Circ Res. 1995 May;76(5):758-66 [7728992.001]
  • [Cites] Exp Eye Res. 2007 Jan;84(1):75-81 [17074321.001]
  • [Cites] Arch Ophthalmol. 2006 Dec;124(12):1711-8 [17159030.001]
  • [Cites] Neurochem Int. 2007 Jan;50(1):211-8 [17014930.001]
  • [Cites] Angiogenesis. 2007;10(2):133-40 [17332988.001]
  • [Cites] Ophthalmic Surg Lasers Imaging. 2007 May-Jun;38(3):233-7 [17552391.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5276-81 [17962483.001]
  • [Cites] Early Hum Dev. 2008 Feb;84(2):107-13 [17513071.001]
  • [Cites] Early Hum Dev. 2008 Feb;84(2):77-82 [18234457.001]
  • (PMID = 21087499.001).
  • [ISSN] 1471-2431
  • [Journal-full-title] BMC pediatrics
  • [ISO-abbreviation] BMC Pediatr
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN18523491; ClinicalTrials.gov/ NCT01079715
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 9Y8NXQ24VQ / Propranolol
  • [Other-IDs] NLM/ PMC2993687
  •  go-up   go-down


74. Kommoss S, Schmidt D, Kommoss F, Hedderich J, Harter P, Pfisterer J, du Bois A: Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). Virchows Arch; 2009 Mar;454(3):249-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).
  • While there is no doubt that histologic grading is applicable in early stage ovarian carcinoma, it is still in controversial discussion concerning advanced stage ovarian carcinoma.
  • It was the aim of this study to assess the three most widely used grading systems for ovarian carcinoma in terms of prognostic significance, concordance rates, and reproducibility in a large number of advanced stage ovarian carcinomas of all types after standardized chemotherapy.
  • Representative hematoxylin and eosin slides from 334 cases of stage IIB-IV ovarian carcinoma (prospective randomized, multi-center, phase III study) were used.
  • Grading of advanced stage ovarian carcinomas was of no value for estimation of prognosis in this homogeneously treated patient group.
  • [MeSH-minor] Aged. Clinical Trials, Phase III as Topic. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Prognosis. Randomized Controlled Trials as Topic. Reproducibility of Results. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2008 Feb;52(3):393-5 [18081817.001]
  • [Cites] Cancer. 1980 Feb;45(3):572-81 [7353206.001]
  • [Cites] Obstet Gynecol. 1982 May;59(5):576-82 [7070728.001]
  • [Cites] APMIS. 1991 Apr;99(4):353-8 [2036219.001]
  • [Cites] Gynecol Oncol. 1984 Jan;17(1):117-23 [6693048.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1168-74 [17667538.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):447-52 [12798710.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):893-901 [9486579.001]
  • [Cites] Anal Quant Cytol Histol. 1986 Dec;8(4):354-7 [3814303.001]
  • [Cites] Histopathology. 2000 May;36(5):433-8 [10792484.001]
  • [Cites] Lancet. 2001 Jan 20;357(9251):176-82 [11213094.001]
  • [Cites] Int J Gynecol Pathol. 2000 Oct;19(4):348-53 [11109164.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):67-71 [16516280.001]
  • [Cites] Acta Obstet Gynecol Scand. 1971;50(1):1-7 [5558593.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] Int J Gynecol Pathol. 1988;7(3):197-211 [2846458.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):175-81 [18317226.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):496-504 [15087669.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):52-6 [12496698.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(2):147-55 [2714932.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] J Obstet Gynaecol Res. 2001 Dec;27(6):313-8 [11794816.001]
  • (PMID = 19172293.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


75. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH: Multidimensional analysis of the learning curve for laparoscopic resection in rectal cancer. J Gastrointest Surg; 2009 Feb;13(2):275-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidimensional analysis of the learning curve for laparoscopic resection in rectal cancer.
  • BACKGROUND: We attempted to assess the learning curve for laparoscopic resection for rectal cancer.
  • METHOD: We included 381 patients who underwent laparoscopic resection for rectal cancer between December 2002 and December 2007.
  • For the patients with stage I-III tumors, the local recurrence rate was 4.4% and the overall recurrence rate was 22.9%.
  • CONCLUSION: The learning curve for laparoscopic surgery for rectal cancer changed over time.
  • [MeSH-minor] Aged. Anal Canal / surgery. Anastomosis, Surgical / adverse effects. Cohort Studies. Colon / surgery. Female. Humans. Male. Middle Aged. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2005 Jul;6(7):477-84 [15992696.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Arch Surg. 1997 Jan;132(1):41-4; discussion 45 [9006551.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S113-6 [18054221.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):666-72 [9708929.001]
  • [Cites] Dis Colon Rectum. 2007 Apr;50(4):464-71 [17195085.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):83-91 [15973105.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Dis Colon Rectum. 2006 Aug;49(8):1108-15 [16763756.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3061-8 [17634484.001]
  • [Cites] Br J Surg. 2003 Jul;90(7):867-71 [12854115.001]
  • [Cites] Dis Colon Rectum. 2001 Feb;44(2):217-22 [11227938.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):7-13 [11961595.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):335-42 [12616116.001]
  • [Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S14-9 [8831541.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1145-9; discussion 1149-50 [15164243.001]
  • [Cites] Dis Colon Rectum. 1997 May;40(5):592-6 [9152190.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Am Surg. 1995 Aug;61(8):681-5 [7618806.001]
  • [Cites] Dis Colon Rectum. 2008 Apr;51(4):385-91 [18219531.001]
  • [Cites] Surg Endosc. 2004 Aug;18(8):1211-5 [15457380.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1371-8; discussion 1378-9 [14530677.001]
  • [Cites] World J Surg. 2007 Sep;31(9):1827-34 [17623232.001]
  • [Cites] Am J Surg. 2004 Jan;187(1):47-51 [14706585.001]
  • [Cites] Surg Endosc. 1995 Nov;9(11):1179-83 [8553229.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):458-63 [11923600.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):315-21 [11289275.001]
  • [Cites] World J Surg. 1996 Mar-Apr;20(3):277-81; discussion 282 [8661831.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1261-6 [14515297.001]
  • [Cites] Am J Surg. 2008 Feb;195(2):233-8 [18083137.001]
  • (PMID = 18941844.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Akasu T, Takawa M, Yamamoto S, Ishiguro S, Yamaguchi T, Fujita S, Moriya Y, Nakanishi Y: Intersphincteric resection for very low rectal adenocarcinoma: univariate and multivariate analyses of risk factors for recurrence. Ann Surg Oncol; 2008 Oct;15(10):2668-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred twenty consecutive patients with T1-T3 rectal cancers located 1-5 (median 3) cm from the anal verge underwent ISR.
  • RESULTS: Fifty patients had disease categorized as stage I, 21 as stage II, 46 as stage III, and 3 as stage IV on the basis of International Union Against Cancer tumor, node, metastasis staging system.
  • The 3-year rates of local and distant recurrence were 6% and 13%, respectively.
  • Univariate analysis of the risk factors for local recurrence revealed pathologic T, pathologic stage, focal dedifferentiation, microscopic resection margins, and preoperative serum CA 19-9 level to be statistically significant.
  • Univariate analysis of the risk factors for distant recurrence indicated tumor location, combined resection, tumor annularity, pathologic N, lateral pelvic lymph node metastasis, pathologic stage, histologic grade, lymphovascular invasion, perineural invasion, and adjuvant chemotherapy to be significant.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Neoplasm Recurrence, Local / diagnosis. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618181.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


77. Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL: Intravesical treatments of bladder cancer: review. Pharm Res; 2008 Jul;25(7):1500-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravesical treatments of bladder cancer: review.
  • For bladder cancer, intravesical chemo/immunotherapy is widely used as adjuvant therapies after surgical transurethal resection, while systemic therapy is typically reserved for higher stage, muscle-invading, or metastatic diseases.
  • To our knowledge, intravesical therapy of bladder cancer represents the first example where computational pharmacological approach was used to design, and successfully predicted the outcome of, a randomized phase III trial (using mitomycin C).

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Urol Nephrol. 1999;31(4):451-6 [10668939.001]
  • [Cites] Gene Ther. 2000 Jan;7(1):31-4 [10680013.001]
  • [Cites] J Urol. 2000 Mar;163(3):761-7 [10687972.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):147-55 [10696253.001]
  • [Cites] Eur Urol. 2000;37 Suppl 3:45-9 [10828687.001]
  • [Cites] Gene Ther. 2000 May;7(10):844-51 [10845722.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8658-63 [10890892.001]
  • [Cites] Eur J Cancer. 2000 Jul;36 Suppl 2:34-7 [10908847.001]
  • [Cites] Urology. 2000 Aug 1;56(2):232-5 [10925084.001]
  • [Cites] Clin Infect Dis. 2000 Sep;31 Suppl 3:S109-14 [11010835.001]
  • [Cites] BJU Int. 2000 Oct;86(6):644-7 [11069370.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4422-31 [11106263.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):597-604 [11309436.001]
  • [Cites] Gene Ther. 2001 Jan;8(1):41-8 [11402300.001]
  • [Cites] Eur Urol. 2001 Jun;39(6):643-7 [11464052.001]
  • [Cites] Oncol Rep. 2001 Sep-Oct;8(5):955-64 [11496299.001]
  • [Cites] J Tongji Med Univ. 2001;21(2):145-8 [11523222.001]
  • [Cites] J Urol. 2004 Mar;171(3):1324-9 [14767342.001]
  • [Cites] Pharm Res. 2004 May;21(5):832-7 [15180342.001]
  • [Cites] Eur Urol. 2004 Jul;46(1):65-71; discussion 71-2 [15183549.001]
  • [Cites] Cancer Gene Ther. 2004 Sep;11(9):594-602 [15272313.001]
  • [Cites] Int J Oncol. 2004 Oct;25(4):1065-71 [15375557.001]
  • [Cites] Mol Ther. 2004 Oct;10(4):697-705 [15451454.001]
  • [Cites] J Urol. 1971 Jul;106(1):72-4 [4998357.001]
  • [Cites] Urol Res. 1976 Apr 21;4(1):9-13 [821200.001]
  • [Cites] Radiology. 1977 May;123(2):475-82 [847220.001]
  • [Cites] Cancer Clin Trials. 1979 Winter;2(4):335-8 [394869.001]
  • [Cites] J Am Osteopath Assoc. 1983 Apr;82(8):570-3 [6682842.001]
  • [Cites] J Pharm Sci. 1983 May;72(5):549-53 [6864504.001]
  • [Cites] Cancer Res. 1984 Oct;44(10):4312-6 [6432309.001]
  • [Cites] J Surg Oncol. 1984 Sep;27(1):67-9 [6434883.001]
  • [Cites] J Surg Oncol. 1985 Apr;28(4):304-7 [3884905.001]
  • [Cites] J Urol. 1986 Apr;135(4):845-6 [3083122.001]
  • [Cites] Urology. 1987 Apr;29(4 Suppl):17-21 [3551281.001]
  • [Cites] Urology. 1988 Mar;31(3 Suppl):26-9 [3126592.001]
  • [Cites] Int J Hyperthermia. 1988 Mar-Apr;4(2):143-58 [3283266.001]
  • [Cites] Actas Urol Esp. 1988 Sep-Oct;12(5):424-9 [3146214.001]
  • [Cites] Urologe A. 1989 Mar;28(2):99-102 [2655259.001]
  • [Cites] J Urol. 1990 Mar;143(3):502-6 [2106041.001]
  • [Cites] Br J Urol. 1990 May;65(5):478-82 [2354313.001]
  • [Cites] Surg Gynecol Obstet. 1990 Dec;171(6):493-6 [2244283.001]
  • [Cites] J Chemother. 1990 Dec;2(6):397-400 [2093114.001]
  • [Cites] Ann Oncol. 1991 Feb;2(2):137-40 [2054316.001]
  • [Cites] J Natl Cancer Inst. 1992 Apr 1;84(7):510-5 [1545441.001]
  • [Cites] Int J Cancer. 1992 May 28;51(3):359-64 [1592527.001]
  • [Cites] Anticancer Drugs. 1992 May;3 Suppl 1:33-7 [1611115.001]
  • [Cites] Urol Res. 1992;20(3):233-6 [1615585.001]
  • [Cites] Eur Urol. 1992;21(3):206-10 [1499626.001]
  • [Cites] Eur Urol. 1992;22(2):112-4 [1478224.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1993;5(1):25-9 [8424911.001]
  • [Cites] Ann Oncol. 1993 Apr;4(4):313-6 [8518222.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3314-20 [8324743.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(4):255-62 [8324866.001]
  • [Cites] Urologe A. 1994 Mar;33(2):138-43 [8178408.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3325-8 [8012943.001]
  • [Cites] J Urol. 1994 Aug;152(2 Pt 1):374-8 [8015074.001]
  • [Cites] Cancer Immunol Immunother. 1994 Jul;39(1):68-70 [8044829.001]
  • [Cites] Anticancer Res. 1996 Mar-Apr;16(2):979-80 [8687163.001]
  • [Cites] Pharm Res. 1996 Dec;13(12):1887-91 [8987090.001]
  • [Cites] Science. 1997 Feb 28;275(5304):1320-3 [9036860.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):875-80 [9041189.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3352-6 [9096397.001]
  • [Cites] Urol Res. 1997;25(2):117-20 [9144878.001]
  • [Cites] J Urol. 1997 Aug;158(2):378-84 [9224307.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(4):285-92 [9225946.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3394-8 [9363871.001]
  • [Cites] Urology. 1998 Mar;51(3):506-9 [9510365.001]
  • [Cites] J Urol. 1998 Aug;160(2):612-4 [9679938.001]
  • [Cites] J Urol. 1998 Nov;160(5):1668-71; discussion 1671-2 [9783928.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):978-85 [15761500.001]
  • [Cites] J Urol. 2005 Jul;174(1):322-7 [15947683.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2140-7 [15928663.001]
  • [Cites] Urology. 2005 Jul;66(1):224-9 [15992886.001]
  • [Cites] Hum Gene Ther. 2005 Aug;16(8):937-46 [16076252.001]
  • [Cites] Urology. 2005 Aug;66(2):461-6 [16040105.001]
  • [Cites] Am J Ophthalmol. 2005 Oct;140(4):585-97 [16226510.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Feb;57(3):328-34 [16028098.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):43-51 [16389183.001]
  • [Cites] J Med Chem. 2006 Jan 12;49(1):349-57 [16392819.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):305-13 [16397056.001]
  • [Cites] Urol Int. 2006;76(2):106-11 [16493208.001]
  • [Cites] Cancer Gene Ther. 2006 Feb;13(2):125-30 [16082384.001]
  • [Cites] Cancer Invest. 2006 Mar;24(2):160-3 [16537185.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2729-34 [16782913.001]
  • [Cites] Urol Oncol. 2006 Jul-Aug;24(4):344-8 [16818189.001]
  • [Cites] Biol Pharm Bull. 2006 Aug;29(8):1685-91 [16880626.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Oct;21(10):1538-43 [16928214.001]
  • [Cites] Int J Pharm. 2006 Sep 28;322(1-2):52-9 [16806751.001]
  • [Cites] Radiother Oncol. 2006 Oct;81(1):9-17 [17011058.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2006 Dec;75(6):367-73 [16930970.001]
  • [Cites] Oncol Rep. 2006 Dec;16(6):1381-8 [17089065.001]
  • [Cites] Chin Med J (Engl). 2006 Oct 20;119(20):1734-9 [17097022.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11219-27 [17145867.001]
  • [Cites] J Surg Res. 2007 Jan;137(1):1-9 [17161985.001]
  • [Cites] J Urol. 2001 Oct;166(4):1291-5 [11547060.001]
  • [Cites] J Urol. 2001 Oct;166(4):1300-4, discussion 1304-5 [11547062.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Jan;29(1):73-80 [11816482.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):957-65 [11844817.001]
  • [Cites] Immunol Lett. 2002 May 1;81(3):235-8 [11947931.001]
  • [Cites] J Urol. 2002 Aug;168(2):813-8 [12131373.001]
  • [Cites] Scand J Urol Nephrol. 2002;36(3):218-22 [12201939.001]
  • [Cites] Nat Biotechnol. 2002 Oct;20(10):1006-10 [12244328.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Oct;50(4):266-70 [12357299.001]
  • [Cites] BJU Int. 2002 Dec;90(9):957-64 [12460364.001]
  • [Cites] J Urol. 2003 Jan;169(1):90-5 [12478111.001]
  • [Cites] J Urol. 2003 Jan;169(1):357-60 [12478189.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1994 Sep;85(9):1353-62 [7967297.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;35 Suppl:S81-3 [7994793.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;35 Suppl:S88-92 [7994795.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):926-8 [7853576.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):959-63 [7853583.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):964-73 [7853584.001]
  • [Cites] J Urol. 1995 Jul;154(1):66-8 [7776458.001]
  • [Cites] Int J Urol. 1995 May;2(2):100-3 [7553280.001]
  • [Cites] J Urol. 1995 Dec;154(6):2050-3 [7500456.001]
  • [Cites] J Urol. 1996 Feb;155(2):753-6 [8558719.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(6):539-46 [8612307.001]
  • [Cites] J Urol. 1996 Jul;156(1):56-9; discussion 59-60 [8648837.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):363-9 [12538489.001]
  • [Cites] J Intern Med. 2003 Jan;253(1):46-75 [12588538.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1291-300 [12684397.001]
  • [Cites] Int J Pharm. 2003 Apr 30;256(1-2):167-73 [12695023.001]
  • [Cites] Drugs R D. 2003;4(3):194-7 [12757408.001]
  • [Cites] Eur Urol. 2003 Jun;43(6):637-45 [12767365.001]
  • [Cites] Can J Urol. 2003 Apr;10(2):1790-5 [12773228.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Jun;51(6):445-50 [12802508.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2247-53 [12805322.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):343-8 [12843796.001]
  • [Cites] J Urol. 2003 Sep;170(3):777-82 [12913696.001]
  • [Cites] Urol Oncol. 2003 Sep-Oct;21(5):354-60 [14670544.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1208-12 [9849481.001]
  • [Cites] Clin Cancer Res. 1997 Jun;3(6):901-9 [9815765.001]
  • [Cites] Urology. 1999 May;53(5):1049-53 [10223504.001]
  • [Cites] Lancet. 1999 Mar 20;353(9157):947-54 [10459902.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1329-34 [10506721.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4912-8 [10519404.001]
  • [Cites] Nucleic Acids Res. 2004;32(19):e149 [15520458.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7244-51 [15534098.001]
  • [Cites] J Urol. 2005 Feb;173(2):604-9 [15643273.001]
  • [Cites] Cancer Immunol Immunother. 2005 May;54(5):414-23 [15565330.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):585-9 [15734775.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2243-50 [15781637.001]
  • (PMID = 18369709.001).
  • [ISSN] 0724-8741
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA111770; United States / NCI NIH HHS / CA / R21CA111770
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 154
  • [Other-IDs] NLM/ PMC2440939
  •  go-up   go-down


78. Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F: Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood; 2010 Aug 12;116(6):886-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six had Rai stage III to IV and were previously heavily treated (median prior therapy = 5).

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2001 Apr 26;165(2):195-200 [11275369.001]
  • [Cites] Blood. 2010 Aug 19;116(7):1083-91 [20442367.001]
  • [Cites] Int Immunopharmacol. 2001 Jun;1(6):1199-210 [11407314.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1755-62 [12685828.001]
  • [Cites] Int Immunopharmacol. 2003 Apr;3(4):541-8 [12689658.001]
  • [Cites] Int Immunopharmacol. 2003 Jun;3(6):879-87 [12781704.001]
  • [Cites] Leukemia. 2004 Mar;18(3):385-93 [14737075.001]
  • [Cites] J Biol Chem. 1969 Feb 25;244(4):644-7 [5768862.001]
  • [Cites] Lancet. 1975 May 3;1(7914):1010-3 [48676.001]
  • [Cites] J Clin Invest. 1980 Jan;65(1):103-8 [6765955.001]
  • [Cites] Cancer Res. 1980 Mar;40(3):588-91 [6937239.001]
  • [Cites] Annu Rev Biochem. 1981;50:845-77 [6267992.001]
  • [Cites] Br J Haematol. 1981 Sep;49(1):23-8 [6974004.001]
  • [Cites] Adv Exp Med Biol. 1986;195 Pt B:191-9 [3094325.001]
  • [Cites] Anal Biochem. 1989 Aug 1;180(2):222-6 [2554751.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Biochemistry. 1998 Jun 16;37(24):8615-21 [9628722.001]
  • [Cites] Immunopharmacology. 1998 Jul;40(1):1-9 [9776473.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3607-15 [9817282.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4253-60 [16131572.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2392-8 [16778146.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1098-105 [18309944.001]
  • [Cites] Leuk Res. 2008 Aug;32(8):1268-78 [18279955.001]
  • [Cites] Blood. 2009 Aug 20;114(8):1563-75 [19541822.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4593-8 [11287638.001]
  • (PMID = 20427701.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00289549
  • [Grant] United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA81534; United States / PHS HHS / / P30-16672
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Purine Nucleosides; 0 / Pyrimidinones; 426X066ELK / forodesine; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase; EC 3.1.3.2 / Phosphoric Monoester Hydrolases; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ PMC2924226
  •  go-up   go-down


79. Piperkova E, Raphael B, Altinyay M, Castellon I, Libes R, Sandella N, Abdel-Dayem H: Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review. J BUON; 2006 Oct-Dec;11(4):523-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review.
  • Distant extrapelvic metastases appear in approximately in 10% of the patients with squamous cell anal cancer (SCAC) and survival depends on the treatment strategy.
  • We present a patient with SCAC in whom, according to PET/CT findings, the initial stage was changed from II (T2N0M0) to III A (T2N2M0).
  • Radiation therapy (RT) and chemotherapy achieved a good therapeutic response but early follow up revealed new paraaortic lymph node (LN) metastases, as well as an uncommon left supraclavicular LN metastasis from the same primary carcinoma.
  • The disease was restaged as stage IV (T2N2M1) and radiation therapy was substituted by chemotherapy.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed